WO2011118699A1 - 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド - Google Patents
免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド Download PDFInfo
- Publication number
- WO2011118699A1 WO2011118699A1 PCT/JP2011/057156 JP2011057156W WO2011118699A1 WO 2011118699 A1 WO2011118699 A1 WO 2011118699A1 JP 2011057156 W JP2011057156 W JP 2011057156W WO 2011118699 A1 WO2011118699 A1 WO 2011118699A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- domain
- amino acid
- immunoglobulin
- affinity
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to a protein that specifically binds to an antibody, an affinity separation matrix using the protein as an immunoglobulin-binding affinity ligand, and a method for separating and purifying or adsorbing antibodies using the matrix.
- the antibody has a function of specifically binding to a substance called an antigen, and a function of detoxifying and removing a factor having the antigen in cooperation with other biomolecules and cells.
- the name “antibody” is a name that emphasizes the function of binding to such an antigen, and the substance is called “immunoglobulin (Ig)”.
- antibody pharmaceuticals using functions of antibodies.
- antibody drugs work more specifically for target molecules, and are expected to reduce side effects and achieve high therapeutic effects. It contributes to the improvement.
- the antibody drugs that have been developed are basically monoclonal antibodies, and are produced in large quantities using recombinant cultured cell technology.
- “Monoclonal antibody” refers to an antibody obtained from a clone derived from a single antibody-producing cell.
- Most antibody drugs currently on the market are immunoglobulin G (IgG) subclass in terms of molecular structure.
- Protein A is well known as an immunoglobulin-binding protein having affinity for IgG antibodies.
- Protein A is one of the cell wall proteins produced by the Gram-positive bacterium Staphylococcus aureus.
- Non-patent Document 1 Signal sequence S, five immunoglobulin binding domains (E domain, D domain, A domain, B) Domain, C domain) and an XM region which is a cell wall binding domain (Non-patent Document 1).
- an affinity chromatography column hereinafter referred to as protein A column
- protein A column in which protein A is immobilized as a ligand on a water-insoluble carrier is generally used ( Non-patent document 1, Non-patent document 2, Non-patent document 3).
- a typical recombinant protein A is recombinant protein A from which the XM region having no immunoglobulin binding activity has been removed (rProtein A Sepharose (registered trademark), manufactured by GE Healthcare Japan, Inc.). Columns using recombinant protein A from which the XM region has been removed as a ligand have the advantage that non-specific adsorption of proteins can be suppressed compared to conventional products, and are currently widely used industrially.
- Patent Document 1 recombinant protein A
- Patent Document 2 recombinant protein A
- a plurality of Lys is mutated as a ligand.
- Non-patent Document 1 Non-patent Document 4, Patent Document 3
- the Z domain is a modified domain in which a mutation that replaces Gly at position 29 with Ala is introduced into the B domain.
- a mutation that replaces Ala at position 1 of the B domain with Val is also introduced at the same time. This is intended to make it easier to produce a coding gene in which a plurality of domains are linked by genetic engineering.
- Patent Document 4 includes an example using a mutant in which Val at the 1st position of the Z domain is replaced with Ala).
- the Z domain is known to have higher alkali resistance than the B domain, and has an advantage in repeated use of the column by washing with an alkaline solution having a high sterilizing and washing effect.
- ligands imparted with further alkali resistance by substituting Asn with other amino acids have been invented (Patent Documents 5 and 6), and industrial use has also begun.
- Non-patent Document 5 Another feature of the Z domain is that the ability to bind to the Fab region of immunoglobulin is weakened (Non-patent Document 5).
- This feature has the advantage that the antibody is easily dissociated in the step of dissociating the bound antibody with an acid (Non-patent Document 1, Patent Document 7). If the antibody is easily dissociated, it is possible to recover a higher concentration of antibody-containing eluate with a smaller volume of eluate. In recent years, the amount of cell culture solution per batch has exceeded 10,000 liters in antibody drug production, and the antibody expression level has been improved to 10 g / L over the past few years (Non-patent Document 6). ). The downstream purification process is also inevitably required to cope with an increase in processing scale, and there is a great expectation for technological improvements that enable recovery of higher concentrations of antibody-containing eluate with a small volume of eluate. Big.
- Patent Document 4 In addition to the Z domain, research based on the C domain of protein A as a modified protein A ligand is underway (Patent Document 4). These ligands are characterized by taking advantage of the high alkali tolerance inherent in the wild-type C domain, and are attracting attention as a new base domain that replaces the Z domain created based on the B domain. . However, as a result of verification on the C domain, it has been found that there is a drawback that the antibody is hardly dissociated in the step of dissociating the antibody bound to the C domain with an acid.
- Non-Patent Document 2 and Patent Document 4 show that the C domain has a strong ability to bind to the Fab region of an immunoglobulin, and this feature is presumed to cause the antibody to be difficult to dissociate with an acid. It was. In order to remedy this drawback, antibody acid dissociation characteristics were verified using a C domain into which a mutation that replaces Gly at position 29 with Ala was introduced. As a result, the antibody was more easily dissociated than the wild type C domain. Although there was a trend, it was still insufficient.
- G29A is known as a mutation that facilitates the dissociation of an antibody from an immunoglobulin-binding domain of protein A.
- G29A has an advantage other than that the antibody is easily dissociated, and technical improvement by mutation to a position other than position 29 is expected.
- the antibody is more easily dissociated by mutation other than position 29.
- the present inventors molecularly designed a number of recombinant protein A mutants having amino acid substitution mutations at positions other than position 29, and used protein engineering techniques and genetic engineering techniques to transform the mutants from transformed cells.
- the present invention was completed by obtaining and comparing the activity of the mutants.
- the present invention relates to an amino acid sequence derived from at least one domain selected from the E, D, A, B, and C domains of protein A described in SEQ ID NOs: 1 to 5, and the A, B, and C domains.
- a protein having an amino acid sequence in which at least one amino acid substitution mutation is introduced into amino acid residues 31 to 37, amino acid residues 29 to 35 of the E domain, or amino acid residues 34 to 40 of the D domain The present invention relates to a protein having affinity for immunoglobulin, characterized in that the affinity for the Fab region of immunoglobulin is reduced compared to the protein before mutagenesis.
- the amino acid sequence derived from the domain before mutagenesis is the amino acid sequence of the E, D, A, B, and C domains of protein A described in SEQ ID NOs: 1 to 5, or the E of protein A described in SEQ ID NOs: 6 to 10. It is preferably an amino acid sequence derived from the D, A, B and C domains.
- the amino acid sequence derived from the domain before mutagenesis is preferably the amino acid sequence of the C domain of protein A described in SEQ ID NO: 5 or the amino acid sequence derived from the C domain of protein A described in SEQ ID NO: 10.
- the amino acid residue corresponding to position 33 of the C domain in each domain is Ser
- the amino acid residue corresponding to position 35 of the C domain in each domain is Lys
- 36 of the C domain in each domain is preferably Asp
- the amino acid residue corresponding to position 37 of the C domain in each domain is Asp.
- Amino acid substitution mutation to be introduced corresponds to mutation that replaces Ser corresponding to position 33 of C domain with Glu, Leu or Thr, mutation that replaces Lys corresponding to position 35 of C domain with Arg, position 36 corresponding to C domain It is preferably a mutation that replaces Asp with Arg or Ile, or a mutation that replaces Asp corresponding to position 37 of the C domain with Glu.
- the amino acid substitution mutation to be introduced is preferably a mutation that substitutes Ser corresponding to position 33 of the C domain with Glu.
- the present invention also relates to a protein comprising a plurality of domains obtained by linking two or more of the proteins.
- proteins to be linked are different types of proteins, and the number of proteins to be linked is 2 to 5.
- the present invention also relates to DNA encoding the protein.
- sequence identity of the base sequences constituting the linked domains is preferably 90% or less.
- the present invention also relates to a vector containing the DNA.
- the present invention also relates to a transformant obtained by transforming a host with the vector.
- the host is preferably a gram-positive bacterium.
- the Gram-positive bacterium is preferably a Brevibacillus bacterium, and the Brevibacillus bacterium is more preferably Brevibacillus choshinensis.
- the present invention also relates to a method for producing the protein, using the transformant or a cell-free protein synthesis system using the DNA.
- the production method it is preferable to accumulate the protein in the cell and / or periplasmic region of the transformant and / or secrete the protein outside the cell of the transformant.
- the present invention also relates to an affinity separation matrix, wherein the protein is immobilized on a carrier comprising a water-insoluble substrate as an affinity ligand.
- the water-insoluble substrate is preferably made of a synthetic polymer or polysaccharide, and the polysaccharide is preferably cellulose.
- the affinity separation matrix preferably binds to a protein containing an immunoglobulin Fc region, and more preferably binds to immunoglobulin G or an immunoglobulin G derivative.
- the present invention also relates to the use of the affinity separation matrix in the separation of a protein containing the Fc region of an immunoglobulin.
- the separation of the protein containing the immunoglobulin Fc region is preferably for the purpose of separating and recovering the protein containing only the immunoglobulin Fab region.
- the protein of the present invention exhibits excellent antibody acid dissociation properties.
- an affinity separation matrix in which the protein is immobilized on a carrier, the separation and purification of the antibody can be improved. Since the protein of the present invention is introduced with mutations at amino acid sites conserved in all domains, the protein of the present invention and the affinity separation matrix are any of E, D, A, B, and C domains. Even when a domain is used, the above-described effects are commonly obtained.
- FIG. 6 is a sensorgram of binding of various GST fusion C domain mutants to monoclonal IgG-Fab (VH3 type) in Biacore measurement according to Example 10 and Comparative Example 3 of the present invention.
- FIG. 10 is a graph relating to 5% dBC for an antibody of an affinity separation matrix (4) according to Example 12 of the present invention.
- FIG. It is the figure which showed the elution peak profile of the antibody refinement
- the protein of the present invention is conserved in all domains in an amino acid sequence derived from at least one domain selected from E, D, A, B, and C domains of protein A described in SEQ ID NOs: 1 to 5.
- Amino acids introduced with at least one amino acid substitution mutation in amino acids 31 to 37 of the A, B, and C domains, amino acids 29 to 35 of the E domain, or amino acids 34 to 40 of the D domain Compared to a protein having a sequence and an amino acid sequence prior to introduction of the mutation, the affinity for the Fab region of the immunoglobulin is reduced and the immunoglobulin has an affinity.
- Protein A is a protein composed of five immunoglobulin-binding domains, that is, five immunoglobulin-binding proteins.
- the E, D, A, B, and C domains of protein A are immunoglobulin binding domains that can bind to regions other than the complementarity determining regions (CDRs) of immunoglobulins. It has an activity of binding to each region of globulin Fc region, Fab region, and particularly Fv region in Fab region.
- the origin of protein A is not particularly limited, but protein A derived from staphylococcus is preferable.
- protein includes any molecule having a polypeptide structure, and a polypeptide chain that is fragmented or linked by peptide bonds is also encompassed by the term “protein”.
- a “domain” is a unit in a higher-order structure of a protein, which is composed of a sequence of several tens to several hundreds of amino acid residues, and is sufficient for expressing any physicochemical or biochemical function. The unit.
- the amino acid sequence derived from the domain refers to the amino acid sequence before the mutation is introduced, and is limited to the wild-type amino acid sequence of any one of the E, D, A, B, and C domains of protein A Instead, even an amino acid sequence partially altered by amino acid substitution, insertion, deletion, and chemical modification is included as long as the protein has the ability to bind to the Fc region.
- Examples of the amino acid sequence derived from the domain include the amino acid sequences constituting the E, D, A, B, and C domains of Staphylococcus protein A described in SEQ ID NOs: 1 to 5. Examples thereof include amino acid sequences constituting E, D, A, B, and C domains of protein A described in 6-10.
- the protein consisting of the amino acid sequences shown in SEQ ID NOs: 6 to 10 corresponds to position 29 of the C domain with respect to the E, D, A, B, and C domains of protein A (SEQ ID NOs: 1 to 5). It is a protein consisting of an amino acid sequence into which a mutation that replaces Gly with Ala is introduced. Further, the Z domain in which the mutations A1V and G29A are introduced into the B domain also has an ability to bind to the Fc region, and therefore corresponds to the amino acid sequence derived from the domain.
- the amino acid sequence before introducing a mutation is preferably a domain with high chemical stability or a mutant thereof.
- a protein into which an amino acid substitution mutation is introduced is preferably a sequence of 85% or more, more preferably 90% or more of an amino acid, and preferably a wild-type amino acid sequence of any of the E, D, A, B, and C domains of protein A It has identity and has the ability to bind to the Fc region.
- Amino acid residues that are conserved in all domains mean the same amino acid residues that are present in the same position when comparing the amino acid sequences of the E, D, A, B, and C domains. As shown in the sequence comparison table of FIG. 1, amino acid residues at positions 26 to 39 in the A, B, and C domains, positions 24 to 37 in the E domain, and positions 29 to 42 in the D domain are Saved. Specific amino acid residues conserved in all domains include, for example, amino acids 31 to 37 of the A, B, and C domains, amino acids 29 to 35 of the E domain, or 34 of the D domain. Examples include amino acids at positions 40 to 40.
- Ser corresponding to position 33 of the C domain Lys corresponding to position 35 of the C domain, Asp corresponding to position 36 of the C domain, and Asp corresponding to position 37 of the C domain are preferable.
- Ser corresponding to position 33 of the C domain is more preferable, but it is not limited thereto. “Corresponding” means that when the E, D, A, B, and C domains of protein A are aligned as shown in FIG.
- a region where an amino acid sequence is highly conserved is often a region important for the function of a protein, and when a mutation is introduced into such a region, the function of the protein is often lost.
- introduction of mutations does not significantly affect the ability of the immunoglobulin to bind to the Fc region, and the immunoglobulin Fab. Only the binding ability to the region can be greatly reduced.
- the amino acid sequence before introducing a mutation is a domain having high chemical stability or a mutant thereof, since the number of amino acids constituting the domain is as few as about 60 amino acids, a new mutation can be introduced. It is a known fact that chemical stability often decreases. For example, a mutant in which Phe at position 30 of the C domain is substituted with Ala is greatly reduced in chemical stability against alkali (Linhult M. et al., PROTEINS: Structure, Function, and Bioinformatics, 2004, 55, 407- 416).
- the amino acid mutation in the present invention can exert the above-described effects while maintaining the inherent chemical stability.
- Amino acid substitution mutation means a mutation that deletes the original amino acid and adds another amino acid of a different type at that position.
- Another amino acid to be added is not particularly limited, and examples thereof include natural protein-constituting amino acids, protein non-constituting amino acids, and non-natural amino acids.
- natural amino acids can be preferably used from the viewpoint of genetic engineering production. Examples of natural amino acids include Ala, Phe, Val, Trp, Leu, Pro, Ile, Met, Gly, Asn, Ser, Gln, Thr, Tyr, Cys, Lys, His, Asp, Glu, and Arg. Particularly preferred is Glu or Arg.
- the number of amino acid substitution mutations is not particularly limited as long as the affinity of the protein containing the mutation for the Fab region of the immunoglobulin is reduced and the affinity for the entire immunoglobulin is maintained. From the viewpoint of maintaining the number, it is preferably 4 or less, more preferably 2 or less.
- G29A a mutation that replaces Gly at position 29 with Ala.
- examples of the introduction include, for example, a mutation that substitutes Ser corresponding to position 33 of the C domain with Glu, Leu, or Thr, C A mutation that replaces Lys corresponding to position 35 of the domain with Arg, a mutation that replaces Asp corresponding to position 36 of the C domain with Arg or Ile, and a mutation that replaces Asp corresponding to position 37 of the C domain with Glu Is mentioned.
- it is preferably a mutation that substitutes Ser corresponding to position 33 of the C domain with Glu, but is not limited thereto.
- a protein obtained by introducing an amino acid substitution mutation is preferably 85% or more, more preferably 90% or more, with the wild-type amino acid sequence of any of E, D, A, B, and C domains of protein A. It has amino acid sequence identity and has the ability to bind to an Fc region.
- the protein of the present invention may be a protein consisting of only a single domain into which an amino acid substitution mutation has been introduced, but two or more of the above proteins may be linked to form a protein consisting of a plurality of domains.
- the protein to be linked may be a protein derived from the same type of domain (homopolymer such as homodimer or homotrimer), or a protein derived from different types of domains (heterodimer, Heteropolymers such as heterotrimers).
- the number of proteins to be linked is preferably 2 or more, more preferably 2 to 10, and even more preferably 2 to 5.
- monomer proteins are linked to each other and single domains are linked by a method that does not involve a linker amino acid residue, or linked by one or more amino acid residues. Examples include, but are not limited to, methods. There is no particular limitation on the number of amino acid residues to be linked. The connection mode and the number of connections are not particularly limited as long as they do not destabilize the three-dimensional structure of the monomeric protein.
- the protein of the present invention also includes a fusion protein in which the protein or the protein composed of a plurality of domains is fused as a constituent component with another protein having different functions.
- fusion proteins include, but are not limited to, proteins in which albumin, GST (glutathione S-transferase), and MBP (maltose binding protein) are fused. By expressing it as a fusion protein with GST and MBP, protein purification can be facilitated.
- a nucleic acid such as a DNA aptamer, a drug such as an antibiotic, and a polymer such as PEG (polyethylene glycol) are also included in the protein of the present invention as long as they have the same effect as the present invention. .
- the present invention also relates to DNA encoding the aforementioned protein.
- the DNA may be any one in which the amino acid sequence obtained by translating the base sequence constituting the DNA constitutes the protein of the present invention.
- a base sequence can be obtained by using a commonly used known method, for example, a polymerase chain reaction (hereinafter abbreviated as PCR) method. It can also be synthesized by a known chemical synthesis method, and can also be obtained from a DNA library.
- the codon may be substituted with a degenerate codon, and as long as it encodes the same amino acid when translated, it does not have to be the same as the original base sequence.
- the DNA of the present invention can be obtained by introducing a site-specific mutation into a conventionally known DNA encoding a wild-type or mutant protein A domain.
- the introduction of site-specific mutations can be performed using recombinant DNA techniques, PCR methods and the like as follows.
- the restriction enzyme recognition sequence is introduced. This can be performed by a cassette mutation method in which a portion is cleaved with the restriction enzyme and a region including a site where mutation is desired is removed, and then a DNA fragment mutated only to the target site by chemical synthesis or the like is inserted.
- site-specific mutation by PCR is, for example, a double double-stranded plasmid in which PCR is performed using a double-stranded plasmid encoding a protein as a template and two kinds of synthetic oligo primers containing mutations complementary to the + and ⁇ strands. This can be done by the primer method.
- a DNA encoding a protein consisting of a plurality of domains can be prepared by linking a desired number of DNAs encoding the monomer protein (one domain) of the present invention in series.
- an appropriate restriction enzyme site can be introduced into a DNA sequence, and double-stranded DNA fragmented with a restriction enzyme can be ligated with DNA ligase.
- a DNA encoding a protein consisting of a plurality of domains can be prepared by applying the above-described mutation introduction method to a DNA encoding protein A (for example, WO 06/004067).
- a DNA encoding protein A for example, WO 06/004067.
- the sequence identity between the nucleotide sequences of DNA encoding the monomeric protein is 90% or less, more preferably 85% or less.
- the vector of the present invention comprises a base sequence encoding the aforementioned protein or a protein consisting of a plurality of domains, and a promoter that can function in a host operably linked to the base sequence. Usually, it can be obtained by ligating or inserting a DNA encoding the aforementioned protein into a vector.
- the vector for inserting the gene is not particularly limited as long as it can replicate autonomously in the host, and plasmid DNA or phage DNA can be used as the vector.
- vectors for inserting genes include pQE vectors (Qiagen), pET vectors (Merck), and pGEX vectors (GE Healthcare Japan ( Vector) and the like.
- pUB110 known as a Bacillus subtilis vector, pHY500 (JP-A-2-31682), pNY700 (JP-A-4-278091), pNU211R2L5 (special) (Kaihei 7-170984), pHT210 (JP-A-6-133782), or pNCMO2 (JP-A 2002-238569), which is a shuttle vector between Escherichia coli and Brevibacillus bacteria, can be used. .
- a transformant can be obtained by transforming a host with a vector.
- the host is not particularly limited, but for mass production at a low cost, Escherichia coli, Bacillus subtilis, Brevibacillus genus, Staphylococcus genus, Streptococcus genus, Streptomyces genus, Corynebacterium genus Bacteria (eubacteria) such as (Corynebacterium) can be preferably used. More preferably, Gram-positive bacteria such as Bacillus subtilis, Brevibacillus genus, Staphylococcus genus, Streptococcus genus, Streptomyces genus, and Corynebacterium genus are preferable. More preferably, a bacterium belonging to the genus Brevibacillus, for which an example of application to mass production of protein A (WO 06/004067) is known, is preferred.
- Brevibacillus genus bacteria are not particularly limited, and examples thereof include Brevibacillus agri, B. et al. borstelensis, B.M. brevis, B.M. centrosporus, B.M. choshinensis, B. et al. formusus, B.M. invocatus, B.M. laterosporus, B.I. limnophilus, B. et al. parabrevis, B.I. reuszeri, B.M. thermorubber.
- Brevibacillus brevis 47 strain JCM6285
- Brevibacillus brevis 47K strain (FERM BP-2308)
- Brevibacillus brevis 47-5Q strain (JCM8970)
- Brevibacillus choshinensis HPD31 strain (FERM BP-1087)
- Brevibacillus choshinensis HPD31-OK strain (FERM BP-4573).
- a mutant strain (or derivative strain) such as a protease-deficient strain, a high-expressing strain, or a spore-forming-deficient strain of the genus Brevibacillus may be used depending on the purpose such as improvement of the production amount. .
- Brevibacillus choshinensis HPD31-derived Brevibacillus choshinensis HPD31-OK Japanese Patent Laid-Open No. 6-296485 which is a protease mutant derived from Brevibacillus choshinensis HPD31, and Brevibacillus choshinensis HPD31 having no spore-forming ability -SP3 (International Publication No. 05/045005) can be used.
- Examples of methods for introducing a vector into a host cell include a method using calcium ions, an electroporation method, a spheroplast method, a lithium acetate method, an Agrobacterium infection method, a particle gun method, or a polyethylene glycol method. However, it is not limited to these.
- examples of a method for expressing the function of the obtained gene in a host include a method for incorporating the gene obtained in the present invention into a genome (chromosome). *
- a protein can be produced by the above-described transformant or a cell-free protein synthesis system using DNA.
- the transformed cell When a protein is produced using a transformant, the transformed cell is cultured in a medium, and is cultured in a culture cell (including the cell periplasm region) or in a culture solution (outside the cell). It can be produced by producing and accumulating proteins, and a desired protein can be collected from the culture.
- the protein When a protein is produced using a transformed cell, the protein can be accumulated in the cell and / or in the periplasmic region of the transformant. In this case, accumulation in the cell is advantageous in that it prevents oxidation of the expressed protein and there is no side reaction with the medium components, and accumulation in the periplasmic region can suppress degradation by intracellular protease. This is advantageous.
- it is also possible to secrete the protein outside the transformant. In this case, the cell disruption and extraction steps are unnecessary, which is advantageous in that the manufacturing cost can be reduced.
- the method of culturing the transformed cell of the present invention in a medium is performed according to a usual method used for host culture.
- the medium used for culturing the obtained transformant is not particularly limited as long as the protein can be produced with high efficiency and high yield.
- carbon sources and nitrogen sources such as glucose, sucrose, glycerol, polypeptone, meat extract, yeast extract, and casamino acid can be used.
- inorganic salts such as potassium salt, sodium salt, phosphate, magnesium salt, manganese salt, zinc salt, iron salt and the like are added as necessary.
- an auxotrophic host cell a nutrient substance required for growth may be added. If necessary, antibiotics such as penicillin, erythromycin, chloramphenicol and neomycin may be added.
- protease inhibitors ie, phenylmethanesulfonylfluoride (PMSF), benzamidine, 4- (2- Aminoethyl) -benzonesulfonyl fluoride (AEBSF), Antipain, Chymostatin, Leupeptin, Pepstatin A, Phosphoramidone, Aprotinin, Ethylenedietate Also good.
- molecular chaperones such as GroEL / ES, Hsp70 / DnaK, Hsp90, Hsp104 / ClpB may be used.
- it can be made to coexist with the protein of the present invention by a technique such as co-expression or fusion proteinization.
- there are techniques such as adding an additive that promotes correct folding to the medium, and culturing at a low temperature. is not.
- LB medium tryptone 1%, yeast extract 0.5%, NaCl 1%
- 2xYT medium tryptone 1.6%, yeast extract 1 0.0%, NaCl 0.5%) and the like.
- TM medium peptone 1%, meat extract 0.5%, yeast extract 0.2%, glucose 1%, pH 7.0
- 2SL medium peptone 4%, yeast extract 0.5%, glucose 2%, pH 7.2
- the culture temperature is 15 to 42 ° C., preferably 20 to 37 ° C.
- the protein of the present invention is cultured in the cultured cells (in the periplasm region) by aerobically culturing for several hours to several days under aeration and stirring conditions. Or accumulated in a culture solution (extracellular) and collected. In some cases, the culture may be performed anaerobically by blocking aeration.
- the recombinant protein produced by separating the cultured cells and the supernatant containing the secreted protein by a general separation method such as centrifugation or filtration after the completion of the culture. can be recovered.
- the cells when accumulated in cultured cells (including in the periplasm region), for example, the cells are collected from the culture solution by a method such as centrifugation or filtration, and then the cells are sonicated.
- the protein accumulated and produced in the cells can be recovered by crushing by a French press method and / or solubilizing by adding a surfactant or the like.
- the cell-free protein synthesis system is not particularly limited.
- a prokaryotic cell-derived, plant cell-derived, higher animal cell-derived synthesis system or the like is used. Can do.
- the protein of the present invention can be purified by affinity chromatography, cation or anion exchange chromatography, gel filtration chromatography or the like alone or in appropriate combination.
- Confirmation that the obtained purified substance is the target protein can be performed by usual methods such as SDS polyacrylamide gel electrophoresis, N-terminal amino acid sequence analysis, Western blotting and the like.
- the protein produced by the above method can be immobilized as an affinity ligand on a carrier comprising a water-insoluble base material to produce an affinity separation matrix.
- affinity ligand is a substance that selectively collects (binds) a target molecule from a set of molecules based on the affinity between specific molecules represented by the binding of an antigen and an antibody. It is a term indicating (functional group), and in the present invention, it refers to a protein that specifically binds to immunoglobulin.
- the expression “ligand” is also synonymous with “affinity ligand”.
- Examples of the carrier composed of a water-insoluble substrate used in the present invention include inorganic carriers such as glass beads and silica gel, crosslinked polymers such as crosslinked polyvinyl alcohol, crosslinked polyacrylate, crosslinked polyacrylamide, and crosslinked polystyrene, crystalline cellulose, crosslinked Examples thereof include organic carriers composed of polysaccharides such as cellulose, crosslinked agarose and crosslinked dextran, and organic-organic, organic-inorganic and other composite carriers obtained by a combination thereof.
- GCL2000 which is a porous cellulose gel
- Sephacryl S-1000 in which allyldextran and methylenebisacrylamide are covalently crosslinked
- Toyopearl which is a methacrylate-based carrier
- Sepharose CL4B which is an agarose-based crosslinked carrier
- Cellufine which is a cellulosic crosslinking carrier.
- the water-insoluble carrier in the present invention is not limited to these exemplified carriers.
- the water-insoluble carrier used in the present invention desirably has a large surface area in view of the purpose and method of use of the affinity separation matrix, and is preferably a porous material having a large number of pores of an appropriate size.
- the form of the carrier can be any of beads, monoliths, fibers, membranes (including hollow fibers), and any form can be selected.
- the method for immobilizing the ligand for example, it may be bound to the carrier by a conventional coupling method using an amino group, a carboxyl group, or a thiol group present in the ligand.
- the support is activated by reacting the support with cyanogen bromide, epichlorohydrin, diglycidyl ether, tosyl chloride, tresyl chloride, hydrazine, sodium periodate, or the like (or on the support surface).
- introducing a reactive functional group a method of immobilizing by coupling reaction with a compound to be immobilized as a ligand, a condensation reagent such as carbodiimide in a system in which a compound to be immobilized as a carrier and a ligand exists, or
- the immobilization method include addition of a reagent having a plurality of functional groups in the molecule such as glutaraldehyde, condensation, and crosslinking.
- a spacer molecule composed of a plurality of atoms may be introduced between the ligand and the carrier, or the ligand may be directly immobilized on the carrier. Therefore, for immobilization, the protein of the present invention may be chemically modified, or an amino acid residue useful for immobilization may be added.
- amino acids useful for immobilization include amino acids having functional groups useful for immobilization chemical reactions in the side chain, such as Lys containing an amino group in the side chain, and thiol groups in the side chain. Cys containing is mentioned.
- the essence of the present invention is that the effect imparted to the protein in the present invention is similarly imparted to the matrix in which the protein is immobilized as a ligand, and no matter how it is modified or altered for immobilization. And within the scope of the present invention.
- the affinity separation matrix is obtained by immobilizing the protein of the present invention, the affinity separation matrix can be bound to a protein containing the Fc region of immunoglobulin based on the activity of the protein of the present invention itself. Therefore, the protein containing the Fc region of immunoglobulin can be separated and purified by affinity column chromatography purification method using the protein of the present invention and the affinity separation matrix.
- a protein containing an Fc region of an immunoglobulin refers to a protein containing a site on the Fc region side to which protein A binds. However, if protein A can be bound, it does not have to be a protein that completely contains the Fc region.
- the protein containing the Fc region of immunoglobulin examples include, but are not limited to, immunoglobulin G or an immunoglobulin G derivative. Specific examples of the protein containing the Fc region of immunoglobulin include IgG belonging to the VH3 subfamily, and in particular, human IgG (monoclonal antibody) belonging to the VH3 subfamily.
- the affinity for the Fab region of IgG belonging to the VH3 subfamily is preferably lower than that of the protein before the mutation is introduced. And preferably has an affinity for the Fc region of IgG, which is 4.
- immunoglobulin G derivative means, for example, a chimeric immunoglobulin G in which a part of the domain of human immunoglobulin G is replaced with a domain of immunoglobulin G of another species and a CDR of human immunoglobulin G (Complementarity Determining Regions) part of a humanized immunoglobulin G in which the CDR part of another species antibody is replaced and fused, immunoglobulin G in which the sugar chain of the Fc region is modified, and the Fv region of human immunoglobulin G It is a generic name for modified artificial proteins to which protein A can bind, such as artificial immunoglobulin G fused with an Fc region.
- the binding region is broadly defined as Fab region (particularly Fv region) and Fc region, since the three-dimensional structure of the antibody is already known, the object to which the protein of the present invention and the affinity separation matrix bind.
- the protein to be obtained may be a protein in which the Fab region or the Fc region is further modified (fragmentation, etc.) while retaining the three-dimensional structure of the region to which protein A binds in terms of protein engineering.
- the method for purifying a protein containing an immunoglobulin Fc region using an affinity column packed with the affinity separation matrix of the present invention is in accordance with an affinity column chromatography purification method using a protein A column that already exists as a commercial product ( Non-patent document 3). That is, after adjusting a buffer containing a protein containing an immunoglobulin Fc region to be neutral, the solution is passed through an affinity column packed with the affinity separation matrix of the present invention, and the immunoglobulin Fc region is passed through. Adsorb protein containing. Next, an appropriate amount of pure buffer is passed through the affinity column, and the inside of the column is washed.
- the protein containing the Fc region of the desired immunoglobulin is adsorbed to the affinity separation matrix of the present invention in the column.
- an acidic buffer adjusted to an appropriate pH (which may contain a substance that promotes dissociation from the matrix) is passed through the column, and the protein containing the Fc region of the desired immunoglobulin is eluted, High purity purification is achieved.
- the affinity separation matrix of the present invention contains an appropriate strong acid or strong alkaline pure buffer (appropriate denaturing agent or organic solvent) that does not completely impair the function of the ligand compound or the carrier substrate. It may be reused by passing it through and washing it.
- the protein of the present invention and the affinity separation matrix using the same have an affinity for immunoglobulin, and have an effect of reducing the affinity for the Fab region of the immunoglobulin.
- each domain of protein A binds more strongly to the Fc region than to the Fab (Fv) region (Non-patent Document 3). Therefore, “affinity to immunoglobulin” of protein A and each domain is an expression essentially indicating affinity for Fc region, and even if only the binding force to Fab region is changed, The strength of affinity does not change greatly.
- the protein of the present invention has a reduced secondary affinity for the Fab region of the immunoglobulin A binding domain of protein A, and can eliminate the influence of secondary binding on the interaction with immunoglobulin. There is an effect.
- the affinity of the protein of the present invention for the immunoglobulin preferably has an affinity constant (KA) of 10 6 (M ⁇ 1 ) or more when the affinity for the human immunoglobulin G preparation is measured by a Biacore system described later. More preferably, it is 10 7 (M ⁇ 1 ) or more.
- the affinity of the protein of the present invention and the affinity separation matrix to the protein containing the Fc region of immunoglobulin is measured by, for example, a biosensor such as a Biacore system (manufactured by GE Healthcare Japan Co., Ltd.) using the surface plasmon resonance principle. It can be tested, but is not limited to this.
- the measurement conditions may be any conditions as long as the binding signal can be detected when protein A binds to the Fc region of an immunoglobulin. It can be easily evaluated by measuring.
- the binding immunoglobulin molecule is not particularly limited as long as the binding to the Fab region can be detected. However, when an immunoglobulin molecule containing an Fc region is used, the binding to the Fc region is also detected. It is preferable to use an immunoglobulin molecule (Fab fragment, Fv fragment) in which the region is fragmented. Furthermore, immunoglobulin Fab fragments belonging to the VH3 subfamily, in which the binding of protein A to the Fab region has already been confirmed, are more preferred.
- the difference in affinity is obtained by obtaining the binding reaction curve for the same immunoglobulin molecule under the same measurement conditions, and the protein before introducing the mutation and the protein after introducing the mutation using the binding parameters obtained when analyzed. Can be easily verified by those skilled in the art.
- the sequences other than the mutation site are the same in both sequences for comparing the difference in affinity.
- the amino acid sequence of the protein before the mutation is introduced If B is the B domain and the amino acid sequence of the protein after the mutation is introduced is a sequence in which the mutation D36R is introduced into the C domain, the comparison is inappropriate.
- an affinity constant (KA) or a dissociation constant (KD) can be used as the binding parameter.
- the affinity constant between the variants of the domains of the present invention and the Fab is obtained by immobilizing an immunoglobulin Fab fragment belonging to the VH3 subfamily on the sensor chip using a Biacore system, Thus, each domain variant can be determined in an experimental system in which a flow path is added.
- a protein in which the affinity constant (KA) of the protein has been reduced to 1 ⁇ 2 or less compared to a protein having a sequence prior to the introduction of the mutation is preferably used.
- the affinity constant is sometimes expressed as a binding constant, but the definition of both is basically the same.
- the C domain mutant Fab in which Gly at position 29 is substituted with Ala has a KA to Fab of 1 ⁇ 10 4 to 1 ⁇ 10 5 (M ⁇ 1 ), but a mutation in which Gly at position 29 is substituted with Ala, and
- the mutant having a KA reduced to less than 1 ⁇ 10 4 (M ⁇ 1 ) can be preferably used in the present invention, and the KA is 0.5 ⁇
- the mutant having 10 4 (M ⁇ 1 ) or less can be more preferably used.
- Fab regions obtained by fragmenting immunoglobulin G into Fab fragments and Fc fragments with papain, or only the Fab region of immunoglobulin G obtained by genetic engineering techniques are expressed.
- Fabs prepared using a production system can be used.
- the affinity separation matrix of the present invention has the property that the binding ability of the immunoglobulin to the Fab region is reduced, the affinity separation matrix is excellent in the property of dissociating the antibody in the step of eluting the antibody with an acidic solution.
- an effect of suppressing damage to the antibody under acidic conditions can be obtained by enabling elution under more acidic side acidic elution conditions. More specifically, the acidic elution conditions on the neutral side are more acidic elution conditions on the more neutral side of pH 3.0 to 5.0 than the normal acidic elution conditions of pH 2.0 to 3.5. It is a condition, and when it is eluted under this condition, the damage to the antibody is small (Gose S.
- the superior antibody acid dissociation characteristics refer to characteristics such that the antibody is dissociated under a more neutral acidic elution condition, and the elution peak profile when the antibody is eluted under an acidic condition is sharper. By making the elution peak profile of chromatography sharper, it is possible to recover a higher concentration of antibody-containing eluate with a smaller volume of eluate.
- affinity separation matrix of the present invention it is possible to easily separate and collect the Fab region as a passing fraction from a mixture comprising a molecule containing the Fc region and a molecule containing only the Fab region.
- the various proteins obtained in the examples are described in the form of “alphabet showing domain-introduced mutation (wild in wild type)”.
- wild type C domain of protein A is expressed as “C-wild”
- C domain mutant introduced with mutation G29A is expressed as “C-G29A”.
- the notation of the mutant in which two kinds of mutations are introduced at the same time is written together using a slash.
- the C domain mutant into which the mutation G29A and the mutation S33E have been introduced are represented in the form of “C-G29A / S33E”.
- a period is added, and the number of linked domains is appended with “d”.
- a protein in which a mutation G29A and a C domain mutant introduced with the mutation S33E are linked in five is denoted as “C-G29A / S33E.5d”.
- C-G29A Preparation of DNA encoding 5d
- Back translation was performed from the amino acid sequence (C-G29V.5d, SEQ ID NO: 11) of a protein in which five C-G29V were linked, and the base sequence encoding the protein was designed.
- HWP Bisu S., “J. Bacteriol.”, 1990, No. 172, 1312-1320
- the codons were distributed in consideration of the frequency of codon usage on page 5 and the sequence identity of the base sequences between the five domains.
- C-G29V A DNA fragment encoding 5d was digested with PstI and XbaI (both manufactured by Takara Bio Inc.), and fractionated and purified by agarose gel electrophoresis.
- pNK3262 which is a plasmid vector for Brevibacillus bacteria, was digested with PstI and XbaI, purified and recovered, and further subjected to dephosphorylation treatment with alkaline phosphatase (Takara Bio). After mixing the two, they were connected using Ligation High (manufactured by Toyobo Co., Ltd.), and C-G29V. 5d expression plasmid vector pNK3262-C-G29V.
- Brevibacillus choshinensis strain FY-1 was transformed using the plasmid vector obtained by the above-described operation. Transformation was carried out by an electrophoretic method according to a known method (“Biosci. Biotech. Biochem.”, 1997, 61, 202-203).
- the Brevibacillus choshinensis FY-1 strain is a Phe ⁇ Tyr auxotrophic strain obtained by mutation treatment of the Brevibacillus choshinensis HPD31-OK strain (Japanese Patent Laid-Open No. 6-296485).
- the gene encoding 5d was divided into 5 and DNA fragments were prepared so as to include Val-29 of each domain. Numbers 1 to 5 are assigned to each domain in order from the N-terminal side. Domain 1 is PstI and NarI, Domain 2 is NarI and HindIII, Domain 3 is HindIII and MluI, Domain 4 is MluI and BglII, Domain 5 is BglII and XbaI (only NarI is made by Toyobo, others are Takara Bio) Each DNA fragment was digested and fractionated and purified on an agarose gel to obtain each DNA fragment.
- pSL301 manufactured by Invitrogen
- pUC19 manufactured by Takara Bio
- pSL301-V29-d3 pSL301-V29-d4
- pSL301-V29-d5 pSL301-V29-d5 corresponding to the numbers assigned to the domains.
- Each C-G29V The sequences of the 5d coding region DNA fragments (including restriction enzyme recognition sites) are shown in SEQ ID NOs: 13-17. *
- the quick change method was performed using the oligonucleotide primers of SEQ ID NOs: 18 to 27 using pUC19-V29-d1, pUC19-V29-d2, pSL301-V29-d3, pSL301-V29-d4, and pSL301-V29-d5 as templates.
- Expression plasmid pNK3262-C-G29A which has a DNA fragment (SEQ ID NO: 29) encoding 5d (SEQ ID NO: 28). 5d was prepared and transformed with FY-1 recombinant bacteria. The quick change method was performed using the DNA polymerase Pfu Turbo and methylated DNA (template DNA) cleaving enzyme DpnI (both manufactured by Stratagene) according to the Stratagene protocol.
- the plasmid pUC19-V29-d1 containing the DNA fragment of SEQ ID NO: 13 was subjected to a quick change method using two synthetic DNA primers of SEQ ID NO: 18 and SEQ ID NO: 19, and domain 1 Plasmid pUC19-A29-d1 containing a DNA fragment in which Val-29 was replaced with Ala was prepared.
- Example 2 C-G29A / S33E. 5d, C-G29A / D36R. 5d and C-G29A / K35R / D37E.
- Preparation of DNA encoding 5d Five plasmids containing the DNA fragment encoding C-G29A prepared in Example 1, pUC19-A29-d1, pUC19-A29-d2, pSL301-A29-d3, pSL301-A29 In the same manner as in Example 1, using the quick change method with C4G29A / S33E, C-, using d4 and pSL301-A29-d5 as templates and the oligonucleotide primers of SEQ ID NOS: 30 to 59 Plasmids containing DNA fragments of G29A / D36R and C-G29A / K35R / D37E were prepared.
- Expression plasmid pNK3262-C-G29A / S33E which has a DNA fragment (SEQ ID NO: 61) encoding 5d (SEQ ID NO: 60). 5d, C-G29A / D36R. Expression plasmid pNK3262-C-G29A / D36R. Which has a DNA fragment (SEQ ID NO: 63) encoding 5d (SEQ ID NO: 62). 5d and C-G29A / K35R / D37E. Expression plasmid pNK3262-C-G29A / K35R / D37E.
- a DNA fragment (SEQ ID NO: 69) encoding 4d (SEQ ID NO: 68) was amplified by PCR. This DNA fragment was digested with PstI and XbaI and inserted into the vector pNK3262 digested with the same enzymes, and the expression plasmid pNK3262-C-G29A / S33E. 4d was prepared and transformed with FY-1 recombinant bacteria.
- Example 3 Confirmation of DNA sequence The DNA sequence of each expression plasmid obtained in Examples 1-2 was confirmed using a DNA sequencer 3130xl Genetic Analyzer (manufactured by Applied Biosystems). BigDye Terminator v. 1.1 Cycle sequencing of each plasmid DNA was performed using Cycle Sequencing Kit (Applied Biosystems) according to the attached protocol, and the sequencing products were purified and used for sequence analysis. The sequence of the oligonucleotide primer used for sequencing is omitted.
- Example 4 Expression of target protein of recombinant recombinant bacteria Various Brevibacillus choshinensis FY-1 recombinant bacteria obtained in Examples 1 and 2 were treated with 5 mL of 3YC medium (polypeptone 3% containing 60 ⁇ g / mL neomycin). And yeast extract 0.2%, glucose 3%, magnesium sulfate 0.01%, iron sulfate 0.001%, manganese chloride 0.001%, zinc chloride 0.0001%) at 30 ° C. for 3 days Culture was performed.
- 3YC medium polypeptone 3% containing 60 ⁇ g / mL neomycin
- yeast extract 0.2%, glucose 3%, magnesium sulfate 0.01%, iron sulfate 0.001%, manganese chloride 0.001%, zinc chloride 0.0001%
- the culture is centrifuged to separate the cells, and the target protein is obtained from the obtained culture supernatant by cation exchange chromatography using an SP Fast Flow column (manufactured by GE Healthcare Japan).
- the target protein was purified by anion exchange chromatography using a DEAE Fast Flow column (manufactured by GE Healthcare Japan). Specifically, the collected target protein solution was dialyzed against ultrapure water and added to a DEAE Fast Flow column equilibrated with anion exchange buffer A (50 mM Tris-HCl, pH 8.0). After washing with anion exchange buffer A, in the middle of a salt concentration gradient using anion exchange buffer A and anion exchange buffer B (50 mM Tris-HCl, 0.3 M NaCl, pH 8.0) The target protein to be eluted was collected. The collected target protein solution was dialyzed again against ultrapure water, and an aqueous solution containing only the target protein was used as the final purified sample. *
- Example 5 Analysis of affinity between acquired protein and human immunoglobulin G (human IgG) Example using biosensor Biacore 3000 (manufactured by GE Healthcare Japan Co., Ltd.) using surface plasmon resonance The affinity of various proteins obtained in 4 with immunoglobulins was analyzed.
- a human immunoglobulin G preparation hereinafter referred to as human IgG
- Human IgG was immobilized on a sensor chip, and various proteins were allowed to flow on the chip to detect their interaction.
- Immobilization of human IgG on the sensor chip CM5 is carried out by an amine coupling method using N-hydroxysuccinimide (NHS) and N-ethyl-N ′-(3-dimethylaminopropyl) carbohydrate hydride (EDC). Ethanolamine was used (sensor chip and immobilization reagent were all manufactured by GE Healthcare Japan Co., Ltd.).
- the human IgG solution was prepared by dissolving Gamma Guard (manufactured by Baxter) in a standard buffer (20 mM NaH 2 PO 4 -Na 2 HPO 4 , 150 mM NaCl, pH 7.4) at 1.0 mg / mL.
- the human IgG solution was diluted 100 times with an immobilization buffer (10 mM CH 3 COOH—CH 3 COONa, pH 4.5), and human IgG was immobilized on the sensor chip according to the protocol attached to Biacore 3000.
- a reference cell serving as a negative control was prepared by performing a process of fixing ethanolamine after activation by EDC / NHS for another flow cell on the chip.
- Various proteins are appropriately prepared in the range of 10 to 1000 nM using a running buffer (20 mM NaH 2 PO 4 -Na 2 HPO 4 , 150 mM NaCl, 0.005% P-20, pH 7.4).
- binding response curve binding response curve obtained by subtracting the binding reaction curves of the reference cell
- the binding parameters of various proteins to human IgG are C-G29A. It was comparable to 5d (Comparative Example 1). Specifically, the affinity constant (KA) for human IgG was within the range of 5.0 ⁇ 10 7 M ⁇ 1 to 5.0 ⁇ 10 8 M ⁇ 1 for any protein.
- a humanized monoclonal IgG preparation as a raw material, it was prepared by fragmenting it into a Fab fragment and an Fc fragment with papain, and separating and purifying only the Fab fragment.
- Herceptin (manufactured by Chugai Pharmaceutical Co., Ltd.), a humanized monoclonal IgG preparation, is dissolved in papain digestion buffer (0.1 M AcOH-AcONa, 2 mM EDTA, 1 mM cysteine, pH 5.5) and immobilized on Papain Agarose from papalatex papain. Agarose (manufactured by SIGMA) was added, and the mixture was incubated at 37 ° C. for about 8 hours while mixing with a rotator.
- papain digestion buffer 0.1 M AcOH-AcONa, 2 mM EDTA, 1 mM cysteine, pH 5.5
- Fab fragments (hereinafter referred to as monoclonal IgG) were subjected to ion exchange chromatography using a Resource S column (manufactured by GE Healthcare Japan Co., Ltd.). -Designated as Fab) and purified. Specifically, a reaction solution diluted to pH 4.5 with ion exchange buffer A (50 mM CH 3 COOH—CH 3 COONa, pH 4.5) was equilibrated with ion exchange buffer A.
- ion exchange buffer A 50 mM CH 3 COOH—CH 3 COONa, pH 4.5
- the fractionated monoclonal IgG-Fab solution was purified by gel filtration chromatography using a Superdex 75 10 / 300GL column (standard buffer was used for equilibration and separation) to obtain a monoclonal IgG-Fab solution.
- Example 6 The monoclonal IgG-Fab obtained in Example 6 was immobilized on the sensor chip CM5, and various proteins obtained in Example 4 were flowed on the chip to detect the interaction.
- Human serum albumin (Sigma Aldrich) was immobilized on the reference cell.
- the method for immobilizing monoclonal IgG-Fab and human serum albumin is the same as in Example 5. *
- Various proteins to be measured are 4 ⁇ M, 8 ⁇ M, 16 ⁇ M, 32 ⁇ M for each using a running buffer (20 mM NaH 2 PO 4 -Na 2 HPO 4 , 150 mM NaCl, 0.005% P-20, pH 7.4). Solutions with different protein concentrations (optionally 32 ⁇ M not yet prepared) were prepared, and each protein solution was added to the sensor chip for 30 seconds at a flow rate of 20 ⁇ L / min. At a measurement temperature of 25 ° C., a binding reaction curve at the time of addition (binding phase, 30 seconds) and after completion of the addition (dissociation phase, 60 seconds) was observed in order.
- the analysis method is the same as that in the sixth embodiment.
- the R max value which is one type of binding parameter at the time of analysis, was fitted as a constant.
- the R max value is the amount of signal when a molecule added to all of the immobilized molecules is bound. In this experimental system in which the same molecule (monoclonal IgG-Fab) is immobilized, this value does not vary greatly. impossible. However, when the binding signal is very weak, an incorrect fitting is performed such that R max becomes an extremely small value, and therefore fitting with the R max value as a constant was performed.
- the binding parameters of various proteins to monoclonal IgG-Fab were C-G29A. It was significantly lower than 5d (Comparative Example 1). Specifically, the affinity constant (KA) for monoclonal IgG-Fab is C-G29A. The value was less than 1/10 compared with 5d.
- Example 8 Preparation of transformed cells for expression of various single domain mutants
- Various variants were prepared at the domain level.
- An amino acid sequence derived from the C domain of protein A (SEQ ID NO: 10, C-G29A.1d) was selected as a protein sequence for introducing a mutation.
- C-G29A A GST fusion protein expression vector pGEX-6P-1 (manufactured by GE Healthcare Japan, Inc.) containing a DNA sequence encoding 1d was used as a template plasmid for mutagenesis.
- the method for preparing the template plasmid is in accordance with the description in the published patent document (International Publication No. 2010/110288).
- oligonucleotide primers of SEQ ID NOs: 71 to 80 and various C domain mutants (C-G29A / S33L.1d, C- Various expression plasmids encoding G29A / S33T.1d, C-G29A / D36I.1d, C-G29A / D36R.1d, C-G29A / D37E.1d) were obtained.
- Example 9 Expression and purification of various single domain type mutants Each transformed cell obtained in Example 8 expresses various mutants as GST fusion proteins. These transformed cells were cultured overnight at 37 ° C. in LB medium containing ampicillin. These cultures were inoculated into 2 ⁇ YT medium (containing ampicillin) and cultured at 37 ° C. for about 1 hour. IPTG (isopropyl 1-thio- ⁇ -D-galacside) was added to a final concentration of 0.1 mM, and further cultured at 37 ° C. for 18 hours. After completion of the culture, the cells were collected by centrifugation and resuspended in a PBS buffer containing EDTA (0.5 mM).
- the cells were disrupted by ultrasonic disruption, centrifuged, and fractionated into a supernatant fraction (cell-free extract) and an insoluble fraction.
- the GST fusion protein is purified by affinity chromatography using a GSTrap FF column (GE Healthcare Japan Co., Ltd.) having affinity for GST ( Crude purification).
- Each cell-free extract is added to a GSTrap FF column, the column is washed with a standard buffer (20 mM NaH 2 PO 4 -Na 2 HPO 4 , 150 mM NaCl, pH 7.4), followed by an elution buffer (50 mM).
- the target GST fusion protein was eluted with Tris-HCl, 20 mM Glutathione, pH 8.0).
- a solution obtained by replacing the elution fraction with a standard buffer by ultrafiltration was used as a final purified sample.
- Example 10 Analysis of affinity of various single-domain mutants with monoclonal IgG-Fab
- monoclonal IgG was obtained in the same manner as described in Example 7.
- -Affinity with Fab was measured with Biacore, and the change in IgG-Fab binding ability by introducing various mutations was analyzed.
- only the sensorgrams of various single domain mutants with a protein concentration of 4 ⁇ M concentration showing the same absorbance at 280 nm
- the obtained IgG-Fab binding sensorgram is shown in FIG.
- the binding response of various proteins to monoclonal IgG-Fab is shown in C-G29A.
- the level was significantly lower and decreased to an undetectable level. It was confirmed that the Fab binding ability was reduced by the mutation obtained by the present invention. Since the binding was reduced to a level where it could not be detected, the affinity constant was not calculated.
- Example 11 C-G29A / S33E. 5d Alkali Resistance Evaluation C-G29A / S33E. The alkali resistance of 5d was evaluated by comparing the degree of decrease in the amount of binding to human IgG (residual binding activity to human IgG) after a treatment for incubation for a certain period of time under alkaline conditions.
- C-G29A / S33E the amount of binding to human IgG before and after alkali treatment was measured using Biacore 3000.
- alkali treatment a fixed amount of 0.625 M NaOH was added to 26.2 ⁇ M of various proteins (10 ⁇ L) so that the final concentration was 0.5 M, and the mixture was incubated at 30 ° C. for 8 hours. Thereafter, 0.5 M HCl (a fixed volume whose pH was confirmed to return to neutral in advance) was neutralized by adding to various treatment solutions, and running buffer (20 mM NaH 2 PO 4 -Na 2 HPO 4 , 150 mM NaCl, 0.005% P-20, pH 7.4), and diluted C-G29A / S33E.
- a 5d solution was prepared.
- the 5d solution was prepared by mixing 26.2 ⁇ M C-G29A / C solution with a mixture of a NaOH solution added at the time of alkali treatment and an HCl solution added at the time of neutralization so that the protein concentration and the composition of the solution would be the same.
- S33E. Prepared by adding to 5d (10 ⁇ L).
- the preparation of the sensor chip (immobilization of human IgG, etc.), the running buffer during measurement, the measurement temperature, and the chip regeneration process are the same as in Example 7.
- the 5d solution was added to the sensor chip for 150 seconds at a flow rate of 20 ⁇ L / min.
- the binding reaction curves at the time of addition (binding phase, 150 seconds) and after the end of addition (dissociation phase, 210 seconds) were observed in order.
- the analysis method is the same as that in Example 5, but the supplementary explanation is given for the interpretation of the obtained binding parameters.
- the protein concentration is the same before and after the alkali treatment, but the protein concentration that has binding activity to human IgG changes. However, since it is difficult to fit the concentration as a variable, the fitting was performed with the concentration being constant before and after the treatment. At this time, the change in the concentration of the protein having binding activity to IgG is reflected in the parameter R max indicating the maximum binding capacity, so that C-G29A / S33E.
- the relative value of R max after alkali treatment residual IgG binding activity [%]
- R max before alkali treatment of 5d was calculated and compared to evaluate alkali resistance.
- C-G29A. 5d (Comparative Example 1) was 85.4%, whereas C-G29A / S33E. 5d was 85.5%. It was confirmed that the mutation of the present invention can exert an effect without impairing the excellent alkali resistance of C-G29A.
- Affinity separation matrix (2) Cross-linked agarose base As a water-insoluble substrate, 1 mL of a commercially available activated prepack column "Hitrap NHS activated HP" (manufactured by GE Healthcare Japan, Inc.) was used. This column is based on cross-linked agarose and has been introduced with N-hydroxysuccinimide (NHS) groups for immobilizing proteinaceous ligands. The C-G29A / S33E.C obtained in Example 4 was almost in accordance with the product manual. The final purified sample of 4d was immobilized as a ligand, and an affinity separation matrix (2) was prepared.
- Hitrap NHS activated HP manufactured by GE Healthcare Japan, Inc.
- a solution obtained by diluting the final purified sample with a coupling buffer (0.2 M sodium carbonate, 0.5 M NaCl, pH 8.3) to a final concentration of about 6 mg / mL was prepared.
- 1 mL of the sample diluted solution prepared above was added at the same flow rate, and the obtained protein was immobilized on the column by plugging the top and bottom of the column and allowing to stand at 25 ° C. for 30 minutes.
- Affinity separation matrix (3) Cellulose base A commercially available gel filtration filler "Cellulofine GCL-2000-m" (manufactured by Chisso Corporation) was used as a water-insoluble substrate. This filler is based on crosslinked porous cellulose. C-G29A / S33E. The final purified sample of 5d was immobilized as a ligand, and an affinity separation matrix (3) was prepared.
- Affinity separation matrix (4) Cellulose base-2 As the water-insoluble substrate, crystalline highly cross-linked cellulose (manufactured by Chisso Corporation, gel obtained by US Publication No. 0062118 (JP 2009-242770)) was used. C-G29A / S33E. The final purified sample of 5d was immobilized as a ligand, and an affinity separation matrix (4) was prepared. Specifically, after replacing 12 mL of gel with a citrate buffer solution (0.01 M trisodium citrate dihydrate-citrate monohydrate, pH 3) on a glass filter, the solution was placed in a centrifuge tube. The amount was 18 mL. To this was added 6 mL of an aqueous solution in which 0.08 g of sodium periodate was dissolved in RO water, and the mixture was shaken with a mix rotor at 6 ° C. for about 30 minutes.
- a citrate buffer solution (0.01 M trisodium citrate dihydrate-citrate monohydrate,
- This carrier is washed on a glass filter using RO water until the electric conductivity of the washing filtrate is 5 ⁇ S / cm or less, and further 0.1 M citric acid aqueous solution (citric acid monohydrate), sodium hydroxide Washed sequentially with a mixed aqueous solution of sodium sulfate (0.05 M NaOH, 0.5 M sodium sulfate) and citrate buffer (0.5 M trisodium citrate dihydrate-citric acid monohydrate, pH 6). Finally, it was washed with RO water until the electric conductivity of the washing filtrate was 5 ⁇ S / cm or less to obtain an affinity separation matrix.
- citric acid aqueous solution citric acid monohydrate
- sodium hydroxide Washed sequentially with a mixed aqueous solution of sodium sulfate (0.05 M NaOH, 0.5 M sodium sulfate) and citrate buffer (0.5 M trisodium citrate dihydrate-citric acid monohydrate, pH 6).
- this affinity separation matrix (4) it attached
- the contact time was 1.8 minutes
- 5% dBC for 3/3 was 33 and 41 mg / mL, respectively, and the amount of ligand leakage was 30 ppm relative to the eluted IgG.
- 5% dBC of a commercially available highly crosslinked agarose carrier “MabSelect” manufactured by GE Healthcare Bioscience measured under the same conditions was 28 and 37 mg / mL, respectively.
- FIG. 3 shows a graph comparing 5% dBC.
- Example 13 Evaluation of antibody acid elution characteristics of various affinity separation matrices Affinity separation matrices (1) to (4) prepared in Example 12 were used as empty column Tricorn TM 5/50 Column (GE Healthcare Japan, Inc.). )) And connected to a chromatographic system AKTA prime plus (manufactured by GE Healthcare Japan Co., Ltd.), and antibody acid elution characteristics were evaluated by antibody purification chromatography.
- the affinity separation matrix (2) is a prepack column, it can be connected as it is. In all cases, the column volume will be about 1 mL.
- the chromatographic profile of the IgG elution peak was confirmed. Furthermore, after continuously flowing 5 mL of standard buffer at the same flow rate, 3 mL of strong washing solution (0.5 M CH 3 COOH, 0.1 M Na 2 SO 4 , pH 2.5) was flowed at the same flow rate, and the absorbance at 280 nm. was monitored to confirm the peak of residual IgG in the column that was forcibly separated.
- the affinity separation matrix (2) only, the composition of the strong washing solution was 20 mM CH 3 COONa-CH 3 COOH, 1M NaCl (pH 3.2).
- affinity separation matrices (1) to (3) antibody acid elution characteristics were evaluated by the same antibody purification chromatography using an elution buffer adjusted to pH 3.75.
- FIG. 4 is a diagram in which elution peak profiles of antibody purification chromatography using each affinity separation matrix (1) immobilized with 5d (Comparative Example 1) are superimposed. The upper figure shows the elution peak profile when the elution pH is 3.5 and the lower figure shows the elution pH of 3.75. As shown in Fig. 4, C-G29A / S33E. The elution peak profile of the matrix with 5d immobilized is C-G29A. Compared to the case of 5d, it was confirmed that it was clearly sharp.
- FIG. 5 is a diagram in which elution peak profiles of antibody purification chromatography using each affinity separation matrix (2) immobilized with 4d (Comparative Example 2) are superimposed.
- C-G29A / S33E The elution peak profile of the matrix with 4d immobilized is C-G29A.
- the sharpness was clear.
- FIG. 6 is a diagram in which the elution peak profiles of antibody purification chromatography using each affinity separation matrix (3) immobilized with 5d (Comparative Example 1) are superimposed.
- the elution peak profile of the matrix with 5d immobilized is C-G29A.
- the protein of the present invention exerts further excellent effects even when combined with a substrate having excellent antibody elution characteristics (dissolution of elution) as a substrate.
- FIG. 7 shows an elution peak profile (elution pH 3.5) of antibody purification chromatography using the affinity separation matrix (4) on which 5d is immobilized.
- C-G29A Preparation and utilization of 5d Using the recombinant bacterium obtained in Example 1, C-G29A.5 was prepared in the same manner as described in Examples 3-5. 5d (SEQ ID NO: 28) was prepared. The method for analyzing affinity with human IgG and monoclonal IgG-Fab is also the same as the method described in Example 5 and Example 7, and the analysis results are shown in Tables 1 and 2 together. did.
- the alkali resistance was also evaluated by the method described in Example 11.
- the preparation of the affinity separation matrix (1), (3) of Example 12 was also performed using C-G29A.
- the antibody acid elution characteristics were evaluated in the same manner as in Example 13 using 5d, and the results are also shown in FIG. 4 and FIG.
- the protein concentration of the solution used was 58.2 mg / mL, and the amount used was 0.79 mL.
- C-G29A Preparation and utilization of 4d Expression plasmid pNK3262-C-G29A.
- C-G29A.5d was prepared in the same manner as in Example 2 using 5d as a template and oligonucleotide primers of SEQ ID NOs: 66 to 67.
- a 4d expression plasmid and its transformed cells were obtained.
- C-G29A. 4d was prepared.
- the preparation of the affinity separation matrix (2) of Example 12 was also performed using C-G29A. 4d was used to evaluate antibody acid elution characteristics in the same manner as in Example 13, and the results are also shown in FIG.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
市販品としては、多孔質セルロースゲルであるGCL2000、アリルデキストランとメチレンビスアクリルアミドを共有結合で架橋したSephacryl S-1000、メタクリレート系の担体であるToyopearl、アガロース系の架橋担体であるSepharose CL4B、および、セルロース系の架橋担体であるCellufineなどを例示することができる。ただし、本発明における水不溶性担体は、例示したこれらの担体のみに限定されるものではない。
また、本発明のアフィニティー分離マトリックスを用いることにより、Fc領域を含む分子とFab領域のみを含む分子からなる混合物から、Fab領域を素通り画分として容易に分離回収することが可能となる。
C-G29Vを5連結したタンパク質のアミノ酸配列(C-G29V.5d、配列番号11)から逆翻訳を行い、該タンパク質をコードする塩基配列を設計した。該タンパク質のコドン使用頻度が、ブレビバチルス・チョウシネンシスHPD31株で大量に発現している細胞表層タンパク質であるHWP(Ebisu S.著、「J.Bacteriol.」、1990年、172号、1312-1320頁)のコドン使用頻度に近くなるように、かつ、5個の各ドメイン間での塩基配列の配列同一性が低くなるように考慮して、コドンを分配した。また、5連結ドメインをコードする配列の5’側にPstI、および、3’側にXbaIの制限酵素認識部位を作製した。DNA断片の作製はタカラバイオ社に依頼した。作製したDNA断片の配列を配列番号12に記した。
実施例1で作製した、C-G29AをコードするDNA断片を含む5種のプラスミド、pUC19-A29-d1、pUC19-A29-d2、pSL301-A29-d3、pSL301-A29-d4、pSL301-A29-d5を鋳型として、配列番号30~59のオリゴヌクレオチドプライマーを用いて、実施例1と同様に、クイックチェンジ法を利用した手法にて、C-G29A/S33E、C-G29A/D36R、および、C-G29A/K35R/D37EのDNA断片を含むプラスミドを作製した。
実施例1~2で得られた、各々の発現プラスミドDNA塩基配列の確認は、DNAシークエンサー3130xl Genetic Analyzer(Applied Biosystems社製)を用いて行った。BigDye Terminator v.1.1 Cycle Sequencing Kit(Applied Biosystems社製)を用いて、付属のプロトコルに従い、各々のプラスミドDNAのシークエンシングPCR反応を行い、そのシークエンシング産物を精製し、配列解析に用いた。シークエンシングに用いたオリゴヌクレオチドプライマーの配列については省略する。
実施例1~2により得られた、各種ブレビバチルス・チョウシネンシスFY-1組み換え菌を、60μg/mLのネオマイシンを含む5mLの3YC培地(ポリペプトン 3%、酵母エキス 0.2%、グルコース 3%、硫酸マグネシウム 0.01%、硫酸鉄 0.001%、塩化マンガン 0.001%、塩化亜鉛 0.0001%)にて、30℃で3日間の振盪培養を行った。
本発明における「Fab領域への親和性」については、免疫グロブリンのFc領域を含まないFabフラグメントを用いて調べた。
実施例4で取得した各種タンパク質のIgG-Fabとの親和性の解析に関しても、実施例5と同様に、Biacore 3000を用いて実施した。
実施例7で評価した変異に加え、この発明によって見出されたその他の変異について効率的に評価することを目的に、単ドメインレベルで各種変異体を調製した。
変異を導入するタンパク質配列として、プロテインAのCドメインに由来するアミノ酸配列(配列番号10、C-G29A.1d)を選んだ。配列番号70に示したC-G29A.1dをコードするDNA配列を含む、GST融合タンパク質発現ベクターpGEX-6P-1(GEヘルスケア・ジャパン(株)製)を変異導入の鋳型プラスミドとした。鋳型プラスミドの調製方法は、公開特許文献(国際公開第2010/110288号公報)の記載に準ずる。
実施例8で得られた各々の形質転換細胞は、各種変異体をGST融合タンパク質として発現する。これらの形質転換細胞を、アンピシリンを含むLB培地にて、37℃で終夜培養した。これらの培養液を、2×YT培地(アンピシリン含有)に接種し、37℃で約1時間培養した。終濃度0.1mMになるようIPTG(イソプロピル1-チオ-β-D-ガラクシド)を添加し、さらに、37℃にて18時間培養した。培養終了後、遠心にて集菌し、EDTA(0.5mM)を含むPBS緩衝液に再懸濁した。超音波破砕にて細胞を破砕し、遠心分離して上清画分(無細胞抽出液)と不溶性画分に分画した。GST融合タンパク質を含む各々の無細胞抽出液から、GSTに対して親和性のあるGSTrap FFカラム(GEヘルスケア・ジャパン(株)製)を用いたアフィニティークロマトグラフィーにて、GST融合タンパク質を精製(粗精製)した。各々の無細胞抽出液をGSTrap FFカラムに添加し、標準緩衝液(20mM NaH2PO4-Na2HPO4,150mM NaCl,pH7.4)にてカラムを洗浄、続いて溶出用緩衝液(50mM Tris-HCl、20mM Glutathione、pH8.0)にて目的のGST融合タンパク質を溶出した。溶出画分を限外ろ過によって標準緩衝液に置換した溶液を、最終精製サンプルとした。
実施例9で得られた各種単ドメイン型変異体について、実施例7に記載の方法と同様に、モノクローナルIgG-Fabとの親和性をBiacoreにて測定し、各種変異を導入することによるIgG-Fab結合能の変化について解析した。ただし、タンパク質濃度を4μM(280nmで同じ吸光度を示す濃度)とした各種単ドメイン型変異体のセンサーグラムのみ測定した。
実施例4で取得したC-G29A/S33E.5dのアルカリ耐性について、アルカリ性条件下で一定時間インキュベートする処理を行った後の、ヒトIgGに対する結合量の低下度合い(ヒトIgGに対する残存結合活性)を比較することで評価した。
アルカリ処理前のC-G29A/S33E.5d溶液は、タンパク質濃度、溶液の組成が同じになるように、アルカリ処理時に加えるNaOH溶液、および、中和処理時に加えるHCl溶液を、あらかじめ混合させた溶液を、26.2μMのC-G29A/S33E.5d(10μL)に対して加えることで、調製した。センサーチップの準備(ヒトIgGの固定化など)、測定時のランニング緩衝液、測定温度、チップの再生処理に関しては、実施例7と同じである。アルカリ処理前、および、処理後のC-G29A/S33E.5d溶液を、流速20μL/minで150秒間センサーチップに添加した。添加時(結合相、150秒間)、および、添加終了後(解離相、210秒間)の結合反応曲線を順次観測した。
アフィニティー分離マトリックス(1):メタクリレート系ポリマー・ベース
水不溶性基材として、市販の活性化型アフィニティークロマトグラフィー用充填剤「TOYOPEARL AF-Formyl-650M」(東ソー(株)製)を使用した。この充填剤は、メタクリレート系ポリマーをベースとし、タンパク性リガンド固定化用のホルミル基が導入済みである。実施例4で取得したC-G29A/S33E.5dの最終精製サンプルをリガンドとして固定化し、アフィニティー分離マトリックス(1)を調製した。
水不溶性基材として、市販の活性化型プレパックカラム「Hitrap NHS activated HP」1mL(GEヘルスケア・ジャパン(株)製)を使用した。このカラムは、架橋アガロースをベースとし、タンパク性リガンド固定化用のN-ヒドロキシスクシンイミド(NHS)基が導入済みである。概ね製品マニュアルに従う形で、実施例4で取得したC-G29A/S33E.4dの最終精製サンプルをリガンドとして固定化し、アフィニティー分離マトリックス(2)を調製した。
水不溶性基材として、市販のゲル濾過用充填剤「セルロファインGCL-2000-m」(チッソ(株)製)を使用した。この充填剤は、架橋された多孔性セルロースをベースとする。実施例4で取得したC-G29A/S33E.5dの最終精製サンプルをリガンドとして固定化し、アフィニティー分離マトリックス(3)を調製した。
水不溶性基材として、結晶性高架橋セルロース(チッソ(株)製、米国公開第0062118号(特開2009-242770)により得られるゲル)を使用した。実施例4で取得したC-G29A/S33E.5dの最終精製サンプルをリガンドとして固定化し、アフィニティー分離マトリックス(4)を調製した。
具体的には、ゲル12mLを、グラスフィルター上にて、クエン酸緩衝液(0.01M クエン酸三ナトリウム二水和物-クエン酸一水和物、pH3)で置換後、遠沈管内で液量を18mLとした。これに0.08gの過ヨウ素酸ナトリウムをRO水に溶解させた水溶液6mLを加え、ミックスローターにて、6℃で約30分間振とうした。
その後、2.4Mクエン酸水溶液(クエン酸1水和物)でpH5とし、6℃で4時間振とうを継続した。続けて、5.5重量%濃度のジメチルアミンボラン水溶液を0.46mL加えて、25℃、18時間振とうした。反応後、反応液の275nm付近の吸収極大の吸光度を測定した結果、C-G29A/S33E.5dの導入量は11mg/mL-gelであり、リガンドの担体への固定化収率は90%であった。
実施例12で調製したアフィニティー分離マトリックス(1)~(4)を、エンプティーカラムTricornTM 5/50 Column(GEヘルスケア・ジャパン(株)製)に充填し、クロマトシステムAKTA prime plus(GEヘルスケア・ジャパン(株)製)に接続して、抗体精製クロマトグラフィーによる抗体酸溶出特性評価を行った。ただし、アフィニティー分離マトリックス(2)はプレパックカラムなので、そのまま接続可能である。全ての場合において、カラム容量は約1mLとなる。このアフィニティー分離カラムを標準緩衝液(20mM NaH2PO4-Na2HPO4、150mM NaCl、pH7.4)で平衡化した後に、VH3サブファミリーに属するヒト化モノクローナルIgG製剤のハーセプチンを標準緩衝液で1mg/mLに調製した溶液500μLを、流速2mL/minにて添加した。その後、標準緩衝液を同じ流速で5mL流して洗浄した後に、溶出緩衝液(35mM CH3COOH-CH3COONa、pH3.5)を同じ流速で5mL流して、280nmの吸光度をモニタリングして得られたIgG溶出ピークのクロマトグラフィー・プロファイルを確認した。さらに連続して、5mLの標準緩衝液を同じ流速で流した後、強洗浄液(0.5M CH3COOH、0.1M Na2SO4、pH2.5)を同じ流速で3mL流し、280nmの吸光度をモニタリングして、強制的に分離されたカラム残存IgGのピークを確認した。なお、アフィニティー分離マトリックス(2)についてのみ、強洗浄液の組成は、20mM CH3COONa-CH3COOH、1M NaCl(pH3.2)とした。
アフィニティー分離マトリックス(1)~(3)については、pH3.75に調整した溶出緩衝液を用いた、同様の抗体精製クロマトグラフィーによる抗体酸溶出特性評価を行った。
C-G29A/S33E.5d、および、C-G29A.5d(比較例1)を固定化した各々のアフィニティー分離マトリックス(1)を用いた、抗体精製クロマトグラフィーの溶出ピーク・プロファイルを重ねた図を、図4に示した。上の図が溶出pH3.5のときの、下の図が溶出pH3.75のときの、溶出ピーク・プロファイルである。図4に示す通り、C-G29A/S33E.5dを固定化したマトリックスの溶出ピーク・プロファイルは、C-G29A.5dの場合に比べて、明確にシャープであることが確認できた。溶出pH3.75のときの溶出ピーク・プロファイルより、変異導入前のC-G29A.5dは吸着したIgGの回収が困難であったものが、変異導入後のC-G29A/S33E.5dでは吸着したIgGを全て回収できることを確認した。本発明がより中性に近い酸性溶液での抗体回収率を劇的に向上することが可能であることを示した一例と考えられる。
C-G29A/S33E.4d、および、C-G29A.4d(比較例2)を固定化した各々のアフィニティー分離マトリックス(2)を用いた、抗体精製クロマトグラフィーの溶出ピーク・プロファイルを重ねた図を、図5に示した。アフィニティー分離マトリックス(1)の場合と同様に、C-G29A/S33E.4dを固定化したマトリックスの溶出ピーク・プロファイルは、C-G29A.4dの場合に比べて、明確にシャープであることが確認できた。本データにより、本発明のタンパク質は、ベースとなる水不溶性基材の種類、基材へのリガンド固定化方法、および、リガンドとなるタンパク質のドメイン数に依らず、効果を奏することが示された。
C-G29A/S33E.5d、および、C-G29A.5d(比較例1)を固定化した各々のアフィニティー分離マトリックス(3)を用いた、抗体精製クロマトグラフィーの溶出ピーク・プロファイルを重ねた図を、図6に示した。C-G29A/S33E.5dを固定化したマトリックスの溶出ピーク・プロファイルは、C-G29A.5dの場合に比べて、明確にシャープであることが確認できた。本データにより、本発明のタンパク質は、基材として抗体溶出特性(溶出の切れ)に優れた基材と組み合わせることによっても、さらに優れた効果が発揮されることが示された。
C-G29A/S33E.5dを固定化したアフィニティー分離マトリックス(4)を用いた、抗体精製クロマトグラフィーの溶出ピーク・プロファイル(溶出pH3.5)を図7に示した。産業的には、高い抗体結合容量を示すマトリックスへのニーズが高く、リガンド固定化量の増加は、抗体結合容量の向上に有効である。本データにより、本発明は、タンパク質固定化量が高い場合においても、問題なくその効果を奏することが確認された。
実施例1で得られた組み換え菌を用いて、実施例3~5に記載の方法と同様の方法にてC-G29A.5d(配列番号28)を調製した。ヒトIgG、および、モノクローナルIgG-Fabとの親和性の解析方法についても、実施例5、および、実施例7に記載の方法と同様であり、解析結果については、表1~2に併せて表記した。
実施例1で得られた発現プラスミドpNK3262-C-G29A.5dを鋳型とし、配列番号66~67のオリゴヌクレオチドプライマーを用いて、実施例2と同様の手法にて、C-G29A.4dの発現プラスミド、および、その形質転換細胞を得た。実施例3~5に記載の方法と同様の方法にて、C-G29A.4dを調製した。加えて、実施例12のアフィニティー分離マトリックス(2)の調製にも、C-G29A.4dを用い、実施例13と同様の手法にて抗体酸溶出特性を評価し、その結果を図5に併せて表記した。
実施例8で用いた鋳型プラスミドを含む形質転換細胞(HB101)を用いて、実施例9と同様の手法にて、C-G29A.1dを調製し、実施例10と同様の手法にて、モノクローナルIgG-Fabとの親和性を解析した。解析結果については、図2に併せて表記した。
Claims (25)
- 配列番号1~5に記載のプロテインAのE、D、A、B及びCドメインから選ばれる少なくとも1つのドメインに由来するアミノ酸配列において、
A、B、および、Cドメインの31~37位のアミノ酸残基、
Eドメインの29~35位のアミノ酸残基、又は
Dドメインの34~40位のアミノ酸残基に
少なくとも1つのアミノ酸置換変異を導入したアミノ酸配列を有するタンパク質であって、
変異導入前のタンパク質と比較して、免疫グロブリンのFab領域に対する親和性が低下していることを特徴とする、免疫グロブリンに親和性を有するタンパク質。 - 変異導入前のドメインに由来するアミノ酸配列が、
配列番号1~5に記載のプロテインAのE、D、A、B及びCドメインのアミノ酸配列、又は
配列番号6~10に記載のプロテインAのE、D、A、B及びCドメインに由来するアミノ酸配列
である、請求項1に記載のタンパク質。 - 変異導入前のドメインに由来するアミノ酸配列が、
配列番号5に記載のプロテインAのCドメインのアミノ酸配列、又は
配列番号10に記載のプロテインAのCドメインに由来するアミノ酸配列
である、請求項1又は2に記載のタンパク質。 - 変異導入前のアミノ酸残基において、
各ドメインにおけるCドメインの33位に対応するアミノ酸残基がSer、
各ドメインにおけるCドメインの35位に対応するアミノ酸残基がLys、
各ドメインにおけるCドメインの36位に対応するアミノ酸残基がAsp、又は
各ドメインにおけるCドメインの37位に対応するアミノ酸残基がAsp
である、請求項1~3のいずれか1項に記載のタンパク質。 - 導入するアミノ酸置換変異が、
Cドメインの33位に対応するSerをGlu、Leu又はThrに置換する変異、
Cドメインの35位に対応するLysをArgに置換する変異、
Cドメインの36位に対応するAspをArg又はIleに置換する変異、又は
Cドメインの37位に対応するAspをGluに置換する変異
である、請求項1~4のいずれか1項に記載のタンパク質。 - 導入するアミノ酸置換変異が、
Cドメインの33位に対応するSerをGluに置換する変異
である、請求項5に記載のタンパク質。 - 請求項1~6のいずれか1項に記載のタンパク質を2個以上連結した複数ドメインからなるタンパク質。
- 連結するタンパク質が、種類の異なるタンパク質である請求項7に記載のタンパク質。
- 連結するタンパク質の数が2~5個である、請求項7または8に記載の複数ドメインからなるタンパク質。
- 請求項1~9のいずれか1項に記載のタンパク質をコードするDNA。
- 連結されているドメインを構成する塩基配列の配列同一性が90%以下であることを特徴とする、請求項10に記載のDNA。
- 請求項10または11に記載のDNAを含むベクター。
- 請求項12に記載のベクターで宿主を形質転換して得られる形質転換体。
- 宿主がグラム陽性菌であることを特徴とする、請求項13に記載の形質転換体。
- グラム陽性菌がブレビバチルス属細菌であることを特徴とする、請求項14に記載の形質転換体。
- ブレビバチルス属細菌がブレビバチルス・チョウシネンシスであることを特徴とする、請求項15に記載の形質転換体。
- 請求項13~16のいずれか1項に記載の形質転換体、または、請求項10又は11に記載のDNAを用いた無細胞タンパク質合成系を用いる、請求項1~9のいずれか1項に記載のタンパク質の製造方法。
- 形質転換体の細胞内及び/又はペリプラズム領域内にタンパク質を蓄積すること、及び/又は、形質転換体の細胞外にタンパク質を分泌することを特徴とする、請求項17に記載の製造方法。
- 請求項1~9のいずれか1項に記載のタンパク質をアフィニティーリガンドとして、水不溶性基材からなる担体に固定化したことを特徴とする、アフィニティー分離マトリックス。
- 水不溶性基材が、合成高分子又は多糖類からなる請求項19に記載のアフィニティー分離マトリックス。
- 多糖類がセルロースである、請求項20に記載のアフィニティー分離マトリックス。
- 免疫グロブリンのFc領域を含むタンパク質に結合することを特徴とする、請求項19~21のいずれか1項に記載のアフィニティー分離マトリックス。
- 免疫グロブリンのFc領域を含むタンパク質が免疫グロブリンG、または、免疫グロブリンG誘導体のいずれかであることを特徴とする、請求項22に記載のアフィニティー分離マトリックス。
- 免疫グロブリンのFc領域を含むタンパク質の分離における、請求項19~23のいずれか1項に記載のアフィニティー分離マトリックスの使用。
- 免疫グロブリンのFc領域を含むタンパク質の分離が、免疫グロブリンのFab領域のみを含むタンパク質の分離回収を目的とする、請求項24に記載のアフィニティー分離マトリックスの使用。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011800153302A CN102844432A (zh) | 2010-03-24 | 2011-03-24 | 特异性结合免疫球蛋白的蛋白质以及免疫球蛋白结合性亲和配体 |
JP2012507056A JP5952185B2 (ja) | 2010-03-24 | 2011-03-24 | 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド |
US13/636,584 US10273270B2 (en) | 2010-03-24 | 2011-03-24 | Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand |
EP11759504.1A EP2557157B1 (en) | 2010-03-24 | 2011-03-24 | Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand |
KR1020127027584A KR101893225B1 (ko) | 2010-03-24 | 2011-03-24 | 면역 글로불린에 특이적으로 결합하는 단백질 및 면역 글로불린 결합성의 친화성 리간드 |
AU2011230313A AU2011230313B2 (en) | 2010-03-24 | 2011-03-24 | Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand |
SG2012070090A SG184184A1 (en) | 2010-03-24 | 2011-03-24 | Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand |
US16/298,639 US20190263870A1 (en) | 2010-03-24 | 2019-03-11 | Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010068870 | 2010-03-24 | ||
JP2010-068870 | 2010-03-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/636,584 A-371-Of-International US10273270B2 (en) | 2010-03-24 | 2011-03-24 | Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand |
US16/298,639 Continuation US20190263870A1 (en) | 2010-03-24 | 2019-03-11 | Protein capable of binding specifically to immunoglobulin, and immunoglobulin-binding affinity ligand |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011118699A1 true WO2011118699A1 (ja) | 2011-09-29 |
Family
ID=44673245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/057156 WO2011118699A1 (ja) | 2010-03-24 | 2011-03-24 | 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド |
Country Status (8)
Country | Link |
---|---|
US (2) | US10273270B2 (ja) |
EP (1) | EP2557157B1 (ja) |
JP (2) | JP5952185B2 (ja) |
KR (1) | KR101893225B1 (ja) |
CN (2) | CN102844432A (ja) |
AU (1) | AU2011230313B2 (ja) |
SG (1) | SG184184A1 (ja) |
WO (1) | WO2011118699A1 (ja) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012122868A (ja) * | 2010-12-09 | 2012-06-28 | Panasonic Corp | 抗原抗体複合体を分離する方法 |
WO2012133342A1 (ja) | 2011-03-25 | 2012-10-04 | 株式会社カネカ | 免疫グロブリン結合性新規ポリペプチド |
JP2013256484A (ja) * | 2012-06-14 | 2013-12-26 | National Institute Of Advanced Industrial Science & Technology | 抗体認識結合タンパク質 |
WO2014034457A1 (ja) | 2012-09-03 | 2014-03-06 | 株式会社カネカ | ミックスモード抗体アフィニティー分離マトリックスとそれを用いた精製方法および標的分子 |
WO2014038686A1 (ja) | 2012-09-10 | 2014-03-13 | 株式会社カネカ | 吸着体 |
WO2014046278A1 (ja) * | 2012-09-21 | 2014-03-27 | 株式会社カネカ | アフィニティー分離マトリックス用タンパク質リガンド |
JP2014185226A (ja) * | 2013-03-22 | 2014-10-02 | San Akuteisu:Kk | β−グルカンの製造方法 |
WO2015034056A1 (ja) | 2013-09-06 | 2015-03-12 | 株式会社カネカ | アフィニティー分離マトリックス用分離能強化リガンド |
WO2015046473A1 (ja) | 2013-09-27 | 2015-04-02 | 株式会社カネカ | アルカリ水溶液を用いた多孔質セルロースビーズの製造方法、リガンド固定化用担体および吸着体 |
JP2015511637A (ja) * | 2012-03-28 | 2015-04-20 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | アフィニティークロマトグラフィーマトリックス |
WO2015056679A1 (ja) | 2013-10-15 | 2015-04-23 | 株式会社カネカ | 多孔質セルロースビーズの製造方法及びそれを用いた吸着体 |
JP2016079149A (ja) * | 2014-10-21 | 2016-05-16 | 株式会社プロテイン・エクスプレス | プロテインl変異体 |
WO2016079034A1 (en) * | 2014-11-17 | 2016-05-26 | Ge Healthcare Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
WO2017014257A1 (ja) * | 2015-07-22 | 2017-01-26 | 株式会社カネカ | 酸性pH領域での抗体結合能が低下した抗体結合性タンパク質 |
WO2017014261A1 (ja) * | 2015-07-22 | 2017-01-26 | 株式会社カネカ | 抗体様タンパク質の精製方法 |
WO2017014259A1 (ja) * | 2015-07-22 | 2017-01-26 | 株式会社カネカ | 酸性pH領域での抗体結合能が低下した抗体結合性タンパク質 |
WO2018088519A1 (ja) * | 2016-11-10 | 2018-05-17 | 株式会社カネカ | 遺伝子導入細胞の製造方法 |
US10065995B2 (en) | 2011-03-25 | 2018-09-04 | Kaneka Corporation | Protein for affinity-separation matrix |
US10519195B2 (en) | 2013-09-17 | 2019-12-31 | Kaneka Corporation | Antibody purification method, antibody obtained therefrom, novel antibody purification method using cation exchanger, and antibody obtained therefrom |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
US10711035B2 (en) | 2016-05-11 | 2020-07-14 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
US10808013B2 (en) | 2015-01-26 | 2020-10-20 | Kaneka Corporation | Mutant immunoglobulin K chain variable region-binding peptide |
US10844112B2 (en) | 2016-05-09 | 2020-11-24 | Kaneka Corporation | Method for purifying antibody or antibody fragment containing κ-chain variable region |
US10858392B2 (en) | 2015-01-26 | 2020-12-08 | Kaneka Corporation | Affinity separation matrix for purifying protein containing immunoglobulin K chain variable region |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
JPWO2019093439A1 (ja) * | 2017-11-09 | 2021-02-18 | 東ソー株式会社 | 免疫グロブリン結合性タンパク質 |
JP2021506928A (ja) * | 2017-12-20 | 2021-02-22 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスの調製方法 |
WO2021075544A1 (ja) | 2019-10-18 | 2021-04-22 | 日本メジフィジックス株式会社 | Ri標識されたヒト化抗体 |
WO2022225006A1 (ja) | 2021-04-21 | 2022-10-27 | 日本メジフィジックス株式会社 | β線を放出する核種で標識されたヒト化抗体 |
WO2022225007A1 (ja) | 2021-04-21 | 2022-10-27 | 日本メジフィジックス株式会社 | 放射性抗腫瘍剤 |
US11623941B2 (en) | 2016-09-30 | 2023-04-11 | Cytiva Bioprocess R&D Ab | Separation method |
US11667671B2 (en) | 2016-05-11 | 2023-06-06 | Cytiva Bioprocess R&D Ab | Separation method |
US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
US11753438B2 (en) | 2016-05-11 | 2023-09-12 | Cytiva Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104059133B (zh) | 2013-03-18 | 2019-03-15 | 南京金斯瑞生物科技有限公司 | 一类突变的具有高耐碱特性的蛋白a及其应用 |
EP2986307A4 (en) | 2014-01-03 | 2017-04-12 | Bio-rad Laboratories, Inc. | Removal of impurities from protein a eluates |
JP6805831B2 (ja) * | 2015-02-05 | 2020-12-23 | 三菱ケミカル株式会社 | 免疫グロブリンに親和性を有するタンパク質、およびそれを用いたアフィニティ分離剤、液体クロマトグラフィー用カラム |
US11208441B2 (en) * | 2015-10-22 | 2021-12-28 | Protenova Co., Ltd. | Immunoglobulin-binding polypeptide |
CN109310780A (zh) | 2016-05-04 | 2019-02-05 | 纳维格蛋白质有限公司 | 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物 |
KR101857953B1 (ko) | 2016-07-06 | 2018-05-16 | 아미코젠주식회사 | 알칼리 내성이 증가된 변이 면역글로불린 결합 단백질 |
CN117736281A (zh) * | 2016-08-11 | 2024-03-22 | 瑞普利金公司 | 用于亲和色谱的碱性稳定性fc结合蛋白 |
GB201708277D0 (en) | 2017-05-24 | 2017-07-05 | Ge Healthcare | A Recombinant protein |
EP3665189A1 (en) | 2017-08-07 | 2020-06-17 | Repligen Corporation | Fc binding proteins with cysteine in the c-terminal helical region |
US11414466B2 (en) | 2017-11-07 | 2022-08-16 | Navigo Proteins Gmbh | Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer |
EP4249097A3 (en) | 2018-02-01 | 2024-01-10 | Repligen Corporation | Fc binding proteins with cysteine in the c-terminal helical region |
WO2020004668A1 (ja) * | 2018-06-29 | 2020-01-02 | 国立大学法人京都工芸繊維大学 | 分離剤 |
EP3816189A4 (en) * | 2018-06-29 | 2021-09-22 | National University Corporation Kyoto Institute of Technology | SEPARATION AGENT |
WO2020232471A2 (en) * | 2019-05-14 | 2020-11-19 | The University Of Chicago | Methods and compositions comprising staphylococcus protein a (spa) variants |
CN112250750B (zh) * | 2020-10-21 | 2022-08-30 | 青岛肿瘤研究院 | 与含酪氨酸磷酸化修饰肽具有亲和力的变体sh2结构域 |
CN115947791A (zh) * | 2021-05-11 | 2023-04-11 | 博格隆(浙江)生物技术有限公司 | 一种重组Protein A蛋白及亲和层析介质的制备方法 |
CN114149495A (zh) * | 2021-12-17 | 2022-03-08 | 博格隆(上海)生物技术有限公司 | 突变的蛋白a结构域c及其应用 |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US62118A (en) | 1867-02-19 | ogden do remus | ||
JPH0231682A (ja) | 1988-01-25 | 1990-02-01 | Juzo Udaka | ヒトegfの製造法 |
US5143844A (en) | 1985-12-13 | 1992-09-01 | Kabigen Ab | Construction of an igg binding protein to facilitate downstream processing using protein engineering |
JPH04278091A (ja) | 1991-03-05 | 1992-10-02 | Higeta Shoyu Kk | 高発現ベクター及び該高発現ベクター を保有する微生物並びに該微生物を 用いる有用物質の製造法 |
JPH06133782A (ja) | 1992-07-23 | 1994-05-17 | Higeta Shoyu Co Ltd | 高発現ベクタ−及び該高発現ベクタ−を 保有する微生物並びに該微生物を用いる 有用物質の製造法 |
JPH06296485A (ja) | 1993-02-22 | 1994-10-25 | Toyota Central Res & Dev Lab Inc | 変異バチルス・ブレビス菌 |
JPH07170984A (ja) | 1992-03-31 | 1995-07-11 | Juzo Udaka | 新規アミノ酸配列及び該アミノ酸配列をコード するdnaを保有する発現ベクターを 組み込んだバチルス・ブレビスを用いる 有用物質の製造法 |
EP1123389A1 (en) | 1998-10-21 | 2001-08-16 | Affibody Technology Sweden AB | A method of affinity separation and ligands for use therein |
US6399750B1 (en) | 1995-11-07 | 2002-06-04 | Pharmacia Biotech Ab | IGG separation medium |
JP2002238569A (ja) | 2001-02-14 | 2002-08-27 | Higeta Shoyu Co Ltd | 大腸菌とブレビバチルス属細菌間のプラスミドシャトルベクター |
WO2003080655A1 (en) | 2002-03-25 | 2003-10-02 | Amersham Biosciences Ab | A mutated immunoglobulin-binding protein |
WO2005045005A1 (ja) | 2003-11-11 | 2005-05-19 | Higeta Shoyu Co., Ltd. | 新規ブレビバチルス・チョウシネンシス及び該微生物を宿主とするタンパク質の製造方法 |
WO2006004067A1 (ja) | 2004-07-06 | 2006-01-12 | Kaneka Corporation | ブレビバチルス属細菌を用いたプロテインa様蛋白質の生産方法 |
JP2006304633A (ja) | 2005-04-26 | 2006-11-09 | Apro Life Science Institute Inc | イムノグロブリン結合タンパク質 |
JP2007252368A (ja) | 2006-02-21 | 2007-10-04 | Protenova Co Ltd | イムノグロブリン親和性リガンド |
JP2009242770A (ja) | 2007-08-31 | 2009-10-22 | Chisso Corp | 多孔性セルロースゲル、その製造方法及びその用途 |
WO2010064437A1 (ja) | 2008-12-03 | 2010-06-10 | 株式会社カネカ | ホルミル基含有多孔質担体、それを用いた吸着体、およびそれらの製造方法 |
WO2010110288A1 (ja) | 2009-03-24 | 2010-09-30 | 株式会社カネカ | 免疫グロブリンに親和性を有するタンパク質および免疫グロブリン結合性アフィニティーリガンド |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525491A (en) * | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
US6602977B1 (en) * | 1999-04-19 | 2003-08-05 | Biovitrum Ab | Receptor structures |
US8674073B2 (en) * | 2006-02-21 | 2014-03-18 | Protenova Co., Ltd. | Immunoglobulin affinity ligand |
CA2664530C (en) * | 2006-09-29 | 2015-11-17 | Ge Healthcare Bio-Sciences Ab | Chromatography ligand comprising domain c from staphyloccocus aureus protein a for antibody isolation |
JP5004165B2 (ja) * | 2006-10-10 | 2012-08-22 | 独立行政法人産業技術総合研究所 | タンパク質の配向制御固定化に適したタンパク質 |
PT3281947T (pt) * | 2009-04-03 | 2020-05-07 | Univ Chicago | Composições e métodos relacionados com variantes da proteína a (spa) |
-
2011
- 2011-03-24 AU AU2011230313A patent/AU2011230313B2/en not_active Ceased
- 2011-03-24 SG SG2012070090A patent/SG184184A1/en unknown
- 2011-03-24 CN CN2011800153302A patent/CN102844432A/zh active Pending
- 2011-03-24 KR KR1020127027584A patent/KR101893225B1/ko active IP Right Grant
- 2011-03-24 EP EP11759504.1A patent/EP2557157B1/en active Active
- 2011-03-24 CN CN201710270110.3A patent/CN107188936B/zh active Active
- 2011-03-24 WO PCT/JP2011/057156 patent/WO2011118699A1/ja active Application Filing
- 2011-03-24 JP JP2012507056A patent/JP5952185B2/ja active Active
- 2011-03-24 US US13/636,584 patent/US10273270B2/en active Active
-
2016
- 2016-03-14 JP JP2016049462A patent/JP6196343B2/ja active Active
-
2019
- 2019-03-11 US US16/298,639 patent/US20190263870A1/en not_active Abandoned
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US62118A (en) | 1867-02-19 | ogden do remus | ||
US5143844A (en) | 1985-12-13 | 1992-09-01 | Kabigen Ab | Construction of an igg binding protein to facilitate downstream processing using protein engineering |
JPH0231682A (ja) | 1988-01-25 | 1990-02-01 | Juzo Udaka | ヒトegfの製造法 |
JPH04278091A (ja) | 1991-03-05 | 1992-10-02 | Higeta Shoyu Kk | 高発現ベクター及び該高発現ベクター を保有する微生物並びに該微生物を 用いる有用物質の製造法 |
JPH07170984A (ja) | 1992-03-31 | 1995-07-11 | Juzo Udaka | 新規アミノ酸配列及び該アミノ酸配列をコード するdnaを保有する発現ベクターを 組み込んだバチルス・ブレビスを用いる 有用物質の製造法 |
JPH06133782A (ja) | 1992-07-23 | 1994-05-17 | Higeta Shoyu Co Ltd | 高発現ベクタ−及び該高発現ベクタ−を 保有する微生物並びに該微生物を用いる 有用物質の製造法 |
JPH06296485A (ja) | 1993-02-22 | 1994-10-25 | Toyota Central Res & Dev Lab Inc | 変異バチルス・ブレビス菌 |
US6399750B1 (en) | 1995-11-07 | 2002-06-04 | Pharmacia Biotech Ab | IGG separation medium |
EP1123389A1 (en) | 1998-10-21 | 2001-08-16 | Affibody Technology Sweden AB | A method of affinity separation and ligands for use therein |
JP2002238569A (ja) | 2001-02-14 | 2002-08-27 | Higeta Shoyu Co Ltd | 大腸菌とブレビバチルス属細菌間のプラスミドシャトルベクター |
WO2003080655A1 (en) | 2002-03-25 | 2003-10-02 | Amersham Biosciences Ab | A mutated immunoglobulin-binding protein |
US20060194950A1 (en) | 2002-03-25 | 2006-08-31 | Sophia Hober | Mutant protein |
WO2005045005A1 (ja) | 2003-11-11 | 2005-05-19 | Higeta Shoyu Co., Ltd. | 新規ブレビバチルス・チョウシネンシス及び該微生物を宿主とするタンパク質の製造方法 |
WO2006004067A1 (ja) | 2004-07-06 | 2006-01-12 | Kaneka Corporation | ブレビバチルス属細菌を用いたプロテインa様蛋白質の生産方法 |
JP2006304633A (ja) | 2005-04-26 | 2006-11-09 | Apro Life Science Institute Inc | イムノグロブリン結合タンパク質 |
JP2007252368A (ja) | 2006-02-21 | 2007-10-04 | Protenova Co Ltd | イムノグロブリン親和性リガンド |
JP2009242770A (ja) | 2007-08-31 | 2009-10-22 | Chisso Corp | 多孔性セルロースゲル、その製造方法及びその用途 |
WO2010064437A1 (ja) | 2008-12-03 | 2010-06-10 | 株式会社カネカ | ホルミル基含有多孔質担体、それを用いた吸着体、およびそれらの製造方法 |
WO2010110288A1 (ja) | 2009-03-24 | 2010-09-30 | 株式会社カネカ | 免疫グロブリンに親和性を有するタンパク質および免疫グロブリン結合性アフィニティーリガンド |
Non-Patent Citations (16)
Title |
---|
BIOSCI. BIOTECH. BIOCHEM., 1997, pages 202 - 203 |
EBISU S., J. BACTERIOL., 1990, pages 1312 - 1320 |
GHOSE S. ET AL., BIOTECHNOLOGY AND BIOENGINEERING, vol. 92, no. 6, 2005 |
HAHN R. ET AL., J. CHROMATOGR. A., vol. 1102, 2006, pages 224 - 231 |
HOBER S. ET AL.: "Protein A chromatography for antibody purification.", J. CHROMATOGR. B ANALYT. TECHNOL. BIOMED. LIFE SCI., vol. 848, 2007, pages 40 - 47, XP005922826 * |
HOBERS. ET AL., J. CHROMATOGR. B, vol. 848, 2007, pages 40 - 47 |
JANSSON B. ET AL., FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, vol. 20, 1998, pages 69 - 78 |
JENDEBERG L. ET AL.: "Kinetic analysis of the interaction between protein A domain variants and human Fc using plasmon resonance detection.", J. MOL. RECOGNIT., vol. 8, no. 4, 1995, pages 270 - 278, XP009024185 * |
JUN-ICHI INAGAWA ET AL., SEPARATION PROCESS ENGINEERING, vol. 38, 2008, pages 201 - 207 |
LINHULT M. ET AL., PROTEINS: STRUCTURE, FUNCTION, AND BIOINFORMATICS, vol. 55, 2004, pages 407 - 416 |
LOW D. ET AL., J. CHROMATOGR. B, vol. 848, 2007, pages 48 - 63 |
NAGATA ET AL.: "Real-time analysis of biomolecular interactions", 1998, SPRINGER-VERLAG, pages: 41 |
NILSSON B. ET AL., PROTEIN ENGINEERING, vol. 1, 1987, pages 107 - 113 |
ROQUE A. C. A. ET AL., J. CHROMATOGR. A, vol. 1160, 2007, pages 44 - 55 |
See also references of EP2557157A4 * |
TASHIRO M. ET AL.: "Structures of bacterial immunoglobulin-binding domains and their complexes with immunoglobulins.", CURR. OPIN. STRUCT. BIOL., vol. 5, 1995, pages 471 - 481, XP008133979 * |
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012122868A (ja) * | 2010-12-09 | 2012-06-28 | Panasonic Corp | 抗原抗体複合体を分離する方法 |
WO2012133342A1 (ja) | 2011-03-25 | 2012-10-04 | 株式会社カネカ | 免疫グロブリン結合性新規ポリペプチド |
EP2690108A1 (en) * | 2011-03-25 | 2014-01-29 | Kaneka Corporation | Novel immunoglobulin-binding polypeptide |
US10065995B2 (en) | 2011-03-25 | 2018-09-04 | Kaneka Corporation | Protein for affinity-separation matrix |
US9284354B2 (en) | 2011-03-25 | 2016-03-15 | Kaneka Corporation | Immunoglobulin-binding polypeptide |
EP2690108A4 (en) * | 2011-03-25 | 2014-12-31 | Kaneka Corp | NOVEL IMMUNOGLOBULIN BINDING POLYPEPTIDE |
JP2015511637A (ja) * | 2012-03-28 | 2015-04-20 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | アフィニティークロマトグラフィーマトリックス |
US10189891B2 (en) | 2012-03-28 | 2019-01-29 | Ge Healthcare Bioprocess R&D Ab | Affinity chromatography matrix |
JP2013256484A (ja) * | 2012-06-14 | 2013-12-26 | National Institute Of Advanced Industrial Science & Technology | 抗体認識結合タンパク質 |
WO2014034457A1 (ja) | 2012-09-03 | 2014-03-06 | 株式会社カネカ | ミックスモード抗体アフィニティー分離マトリックスとそれを用いた精製方法および標的分子 |
US9890191B2 (en) | 2012-09-03 | 2018-02-13 | Kaneka Corporation | Mixed-mode antibody affinity separation matrix and purification method using the same, and the target molecules |
WO2014038686A1 (ja) | 2012-09-10 | 2014-03-13 | 株式会社カネカ | 吸着体 |
WO2014046278A1 (ja) * | 2012-09-21 | 2014-03-27 | 株式会社カネカ | アフィニティー分離マトリックス用タンパク質リガンド |
US9920098B2 (en) | 2012-09-21 | 2018-03-20 | Kaneka Corporation | Protein ligand for affinity isolation matrix |
JP2014185226A (ja) * | 2013-03-22 | 2014-10-02 | San Akuteisu:Kk | β−グルカンの製造方法 |
WO2015034056A1 (ja) | 2013-09-06 | 2015-03-12 | 株式会社カネカ | アフィニティー分離マトリックス用分離能強化リガンド |
US10519195B2 (en) | 2013-09-17 | 2019-12-31 | Kaneka Corporation | Antibody purification method, antibody obtained therefrom, novel antibody purification method using cation exchanger, and antibody obtained therefrom |
WO2015046473A1 (ja) | 2013-09-27 | 2015-04-02 | 株式会社カネカ | アルカリ水溶液を用いた多孔質セルロースビーズの製造方法、リガンド固定化用担体および吸着体 |
WO2015056679A1 (ja) | 2013-10-15 | 2015-04-23 | 株式会社カネカ | 多孔質セルロースビーズの製造方法及びそれを用いた吸着体 |
JP2016079149A (ja) * | 2014-10-21 | 2016-05-16 | 株式会社プロテイン・エクスプレス | プロテインl変異体 |
WO2016079034A1 (en) * | 2014-11-17 | 2016-05-26 | Ge Healthcare Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
JP2017536819A (ja) * | 2014-11-17 | 2017-12-14 | ジーイー・ヘルスケア・バイオプロセス・アールアンドディ・アクチボラグ | 変異免疫グロブリン結合ポリペプチド |
KR20170085502A (ko) * | 2014-11-17 | 2017-07-24 | 지이 헬스케어 바이오프로세서 알&디 에이비 | 돌연변이된 이뮤노글로불린-결합 폴리펩티드 |
KR102697609B1 (ko) | 2014-11-17 | 2024-08-26 | 씨티바 바이오프로세스 알&디 에이비 | 돌연변이된 이뮤노글로불린-결합 폴리펩티드 |
CN107001432B (zh) * | 2014-11-17 | 2022-02-18 | 思拓凡生物工艺研发有限公司 | 突变的免疫球蛋白结合多肽 |
JP2020184999A (ja) * | 2014-11-17 | 2020-11-19 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 変異免疫グロブリン結合ポリペプチド |
RU2712882C2 (ru) * | 2014-11-17 | 2020-01-31 | ДжиИ Хелткер Биопроцесс АрЭндДи АБ | Мутантные иммуноглобулин-связывающие полипептиды |
CN107001432A (zh) * | 2014-11-17 | 2017-08-01 | 通用电气医疗集团生物工艺研发股份公司 | 突变的免疫球蛋白结合多肽 |
US10858392B2 (en) | 2015-01-26 | 2020-12-08 | Kaneka Corporation | Affinity separation matrix for purifying protein containing immunoglobulin K chain variable region |
US10808013B2 (en) | 2015-01-26 | 2020-10-20 | Kaneka Corporation | Mutant immunoglobulin K chain variable region-binding peptide |
WO2017014257A1 (ja) * | 2015-07-22 | 2017-01-26 | 株式会社カネカ | 酸性pH領域での抗体結合能が低下した抗体結合性タンパク質 |
WO2017014261A1 (ja) * | 2015-07-22 | 2017-01-26 | 株式会社カネカ | 抗体様タンパク質の精製方法 |
WO2017014259A1 (ja) * | 2015-07-22 | 2017-01-26 | 株式会社カネカ | 酸性pH領域での抗体結合能が低下した抗体結合性タンパク質 |
JPWO2017014259A1 (ja) * | 2015-07-22 | 2018-04-26 | 株式会社カネカ | 酸性pH領域での抗体結合能が低下した抗体結合性タンパク質 |
JPWO2017014261A1 (ja) * | 2015-07-22 | 2018-04-26 | 株式会社カネカ | 抗体様タンパク質の精製方法 |
JPWO2017014257A1 (ja) * | 2015-07-22 | 2018-05-10 | 株式会社カネカ | 酸性pH領域での抗体結合能が低下した抗体結合性タンパク質 |
US10844112B2 (en) | 2016-05-09 | 2020-11-24 | Kaneka Corporation | Method for purifying antibody or antibody fragment containing κ-chain variable region |
US10995113B2 (en) | 2016-05-11 | 2021-05-04 | Cytiva Bioprocess R&D Ab | Separation matrix |
US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
US12037359B2 (en) | 2016-05-11 | 2024-07-16 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
US11753438B2 (en) | 2016-05-11 | 2023-09-12 | Cytiva Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
US11685764B2 (en) | 2016-05-11 | 2023-06-27 | Cytiva Bioprocess R&D Ab | Separation matrix |
US10711035B2 (en) | 2016-05-11 | 2020-07-14 | Ge Healthcare Bioprocess R&D Ab | Separation matrix |
US11667671B2 (en) | 2016-05-11 | 2023-06-06 | Cytiva Bioprocess R&D Ab | Separation method |
US11623941B2 (en) | 2016-09-30 | 2023-04-11 | Cytiva Bioprocess R&D Ab | Separation method |
JP7189770B2 (ja) | 2016-11-10 | 2022-12-14 | 株式会社カネカ | 遺伝子導入細胞の製造方法 |
WO2018088519A1 (ja) * | 2016-11-10 | 2018-05-17 | 株式会社カネカ | 遺伝子導入細胞の製造方法 |
US11155833B2 (en) | 2016-11-10 | 2021-10-26 | Kaneka Corporation | Method for producing transgenic cell |
JPWO2018088519A1 (ja) * | 2016-11-10 | 2019-10-03 | 株式会社カネカ | 遺伝子導入細胞の製造方法 |
JP7306270B2 (ja) | 2017-11-09 | 2023-07-11 | 東ソー株式会社 | 免疫グロブリン結合性タンパク質 |
JPWO2019093439A1 (ja) * | 2017-11-09 | 2021-02-18 | 東ソー株式会社 | 免疫グロブリン結合性タンパク質 |
JP7309252B2 (ja) | 2017-12-20 | 2023-07-18 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスの調製方法 |
JP2021506928A (ja) * | 2017-12-20 | 2021-02-22 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスの調製方法 |
WO2021075544A1 (ja) | 2019-10-18 | 2021-04-22 | 日本メジフィジックス株式会社 | Ri標識されたヒト化抗体 |
WO2022225007A1 (ja) | 2021-04-21 | 2022-10-27 | 日本メジフィジックス株式会社 | 放射性抗腫瘍剤 |
WO2022225006A1 (ja) | 2021-04-21 | 2022-10-27 | 日本メジフィジックス株式会社 | β線を放出する核種で標識されたヒト化抗体 |
Also Published As
Publication number | Publication date |
---|---|
AU2011230313A1 (en) | 2012-10-25 |
CN102844432A (zh) | 2012-12-26 |
US20190263870A1 (en) | 2019-08-29 |
SG184184A1 (en) | 2012-10-30 |
JPWO2011118699A1 (ja) | 2013-07-04 |
KR101893225B1 (ko) | 2018-08-29 |
JP2016117761A (ja) | 2016-06-30 |
EP2557157A4 (en) | 2013-09-04 |
KR20130028083A (ko) | 2013-03-18 |
JP6196343B2 (ja) | 2017-09-13 |
CN107188936A (zh) | 2017-09-22 |
JP5952185B2 (ja) | 2016-07-13 |
CN107188936B (zh) | 2021-08-10 |
US10273270B2 (en) | 2019-04-30 |
EP2557157A1 (en) | 2013-02-13 |
US20130096276A1 (en) | 2013-04-18 |
AU2011230313B2 (en) | 2015-01-22 |
EP2557157B1 (en) | 2017-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6196343B2 (ja) | 免疫グロブリンに特異的に結合するタンパク質および免疫グロブリン結合性アフィニティーリガンド | |
JP6184463B2 (ja) | 免疫グロブリンに親和性を有するタンパク質および免疫グロブリン結合性アフィニティーリガンド | |
JP2017070289A (ja) | アフィニティー分離マトリックス用タンパク質 | |
JP5933526B2 (ja) | 免疫グロブリン結合性新規ポリペプチド | |
JP6464089B2 (ja) | アフィニティー分離マトリックス用分離能強化リガンド | |
US20180215785A1 (en) | Method for purifying antibody-like protein | |
JPWO2016136910A1 (ja) | 改変型Fab領域結合性ペプチド | |
WO2017014260A1 (ja) | 酸性pH領域での抗体結合能が低下した抗体結合性タンパク質 | |
JP6861155B2 (ja) | 酸性pH領域での抗体結合能が低下した抗体結合性タンパク質 | |
WO2017022759A1 (ja) | 免疫グロブリン結合性改変型タンパク質 | |
WO2017014259A1 (ja) | 酸性pH領域での抗体結合能が低下した抗体結合性タンパク質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180015330.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11759504 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012507056 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2864/KOLNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 20127027584 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2011759504 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011759504 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2011230313 Country of ref document: AU Date of ref document: 20110324 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13636584 Country of ref document: US |